UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DCD.C. 20549

FORM 10-Q

(Mark One)

☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~June~~September 30, ~~2020~~2023

☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ________________ to ________________

Commission File Number: ~~001-38561~~001-39336

~~Aditx Therapeutics,~~Aditxt, Inc.

(Exact name of registrant as specified in its charter)

Delaware		82-3204328
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

737 N. Fifth Street, Suite 200 Richmond, VA		23219

~~11161 Anderson Street~~ ~~Suite 105-10014~~ ~~Loma Linda, CA 92354~~		~~92354~~
(Address of principal executive offices)		(Zip Code)

~~(909) 488-0844~~(650) 870-1200

(Registrant’s telephone number, including area code)

~~N/A~~Not applicable

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock,

par value $0.001 per share

ADTX

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically ~~and posted on its corporate Web site, if any,~~ every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of ~~August 12, 2020,~~November 13, 2023, the registrant had ~~7,078,817~~441,902 and ~~6,978,014~~441,851 shares of common stock, $0.001 par value per share, issued and outstanding, respectively.

Table of Contents

INDEX			Page No.

Cautionary Note Regarding Forward-Looking Statements and Industry Data			ii

PART I FINANCIAL INFORMATION
Item 1.	Condensed Consolidated Financial Statements (Unaudited)		1
~~Item 1.~~	~~Financial Statements (Unaudited)~~	1
	Condensed Consolidated Balance Sheets as of ~~June~~September 30, ~~2020~~2023 and December 31, ~~2019~~2022		1
	Condensed Consolidated Statements of Operations for the three and ~~six~~nine months ended ~~June~~September 30, ~~2020~~2023 and ~~2019~~2022		2
	~~Statement~~Condensed Consolidated Statements of Stockholders’ ~~Deficit~~Equity (Deficit) for the ~~six~~three and nine months ended ~~June~~September 30, ~~2020~~2023 and ~~2019~~2022		3
	Condensed Consolidated Statements of Cash Flows for the ~~six~~nine months ended ~~June~~September 30, ~~2020~~2023 and ~~2019~~2022	4
	~~Notes to Financial Statements~~	5
	Notes to Condensed Consolidated Financial Statements		6
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	15	27
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	21	35
Item 4.	Controls and Procedures	21	35

PART II OTHER INFORMATION		22
Item 1.	Legal Proceedings	22	36
Item 1A.	Risk Factors	22	36
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	22	38
Item 3.	Defaults Upon Senior Securities	23	39
Item 4.	Mine Safety Disclosures	23	39
Item 5.	Other Information	23	39
Item 6.	Exhibits	23	39

Signatures		24	40

~~-i-~~

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY DATA

This Quarterly Report on Form 10-Q contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These statements may be identified by such forward-looking terminology as “may,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue” or the negative of these terms or other comparable terminology. Our forward-looking statements are based on a series of expectations, assumptions, estimates and projections about our company, are not guarantees of future results or performance and involve substantial risks and uncertainty. We may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements. Our business and our forward-looking statements involve substantial known and unknown risks and uncertainties, including the risks and uncertainties inherent in our statements regarding:

●

~~Our plans~~we have generated no significant revenue from commercial sales to ~~initiate~~date and our future profitability is uncertain;

●

if we fail to obtain the capital necessary to fund our operations, we will be unable to continue or complete our product development, execute on our strategic M&A initiatives, commence our planned clinical trials and you will likely lose your entire investment;

●

our financial situation creates doubt whether we will continue as a going concern;

●

we may need to raise additional funding, which may not be available on acceptable terms, or at all;

●

even if we can raise additional funding, we may be required to do so on terms that are dilutive to you;

●

the regulatory approval process is expensive, time-consuming and uncertain and may prevent us from obtaining approvals for the commercialization of our future product ~~candidates;~~candidates, if any;

●

we may encounter substantial delays in completing our clinical studies which in turn will require additional costs, or we may fail to demonstrate adequate safety and efficacy to the satisfaction of applicable regulatory authorities;

●

~~Our plans~~if our future pre-clinical development and future clinical Phase I/II studies are unsuccessful, we may be unable to ~~research, develop and~~obtain regulatory approval of, or commercialize, our product candidates on a timely basis or at all;

●

~~Our ability to comply with the provisions of our license agreement with Loma Linda University;~~

●

~~The results of clinical testing and trial activities~~even if we receive regulatory approval for any of our product ~~candidates;~~candidates, we may not be able to successfully commercialize the product and the revenue that we generate from their sales, if any, may be limited;

●

adverse events involving our products may lead the FDA or applicable foreign regulatory agency to delay or deny clearance for our products or result in product recalls that could harm our reputation, business and financial results;

●

our technology is subject to licenses from LLU and Stanford (as defined below), each of which are revocable in certain circumstances, including in the event we do not achieve certain payments and milestone deadlines. Without these licenses, we may not be able to continue to develop our product candidates;

●

if we were to lose our CLIA certification or state laboratory licenses, whether as a result of a revocation, suspension or limitation, we would no longer be able to offer our assays (including our AditxtScore™ platform), which would limit our revenues and harm our business. If we were to lose, or fail to obtain, a license in any other state where we are required to hold a license, we would not be able to test specimens from those states;

●

our results of operations will be affected by the level of royalty and milestone payments that we are required to pay to third parties;

●

we face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do;

●

our technologies and products under development, and our business, may fail if we are not able to successfully commercialize them and ultimately generate significant revenues as a result;

●

customers may not adopt our products quickly, or at all;

●

~~Our~~COVID-19 may impact our business and operations;

●

the failure to obtain or maintain patents, licensing agreements and other intellectual property could materially impact our ability to ~~obtain regulatory approval and market acceptance of, and reimbursement for our products;~~compete effectively;

●

~~Our ability to protect~~some of our intellectual property ~~and~~may be subject to ~~develop, maintain and enhance a strong brand;~~“march-in” rights by the U.S. federal government;

●

~~Our ability~~we do not expect to ~~compete and succeed~~pay dividends in ~~a highly competitive and evolving industry;~~the foreseeable future;

●

~~Our lack~~we have issued a significant number of ~~operating history on which~~restricted stock awards, restricted stock units, options and warrants and may continue to ~~judge our business prospects~~do so in the future. The vesting and, ~~management;~~

●

~~Our ability to raise capital~~if applicable, exercise of these securities and the ~~availability~~sale of the shares of common stock issuable thereunder may dilute your percentage ownership interest and may also result in downward pressure on the price of our common stock;

●

future sales or issuances of substantial amounts of our common stock, including, potentially as a result of future ~~financing;~~acquisitions or strategic transactions, could result in significant dilution;

●

~~Our ability~~while we have entered into an Asset Purchase Agreement with Cellvera Global, we cannot assure you that the transaction contemplated by the Asset Purchase Agreement will be consummated or, that if such transaction is consummated, that it will be accretive to ~~manage our research, development, expansion, growth and operating expenses;~~stockholder value;

●

~~Our reliance on third parties~~we have provided loans to ~~conduct our research, preclinical studies and expected clinical trials; and~~Cellvera Global in the principal amount of $14.5 million, if we are unable to complete the transactions contemplated by the Asset Purchase Agreement, we cannot provide any assurance that we will be able to timely collect such amounts from Cellvera Global, if at all;

●

we may engage in future acquisitions or strategic transactions, including the ~~impacts of COVID-19,~~transaction with Cellvera Global, which may require us to seek additional financing or ~~other future pandemics on~~financial commitments, increase our ~~business;~~expenses and/or present significant distractions to our management;

●

~~the impact~~exclusive forum provisions in our amended and restated certificate of ~~government laws~~incorporation and ~~regulation.~~amended and restated bylaws.

All of our forward-looking statements are as of the date of this Quarterly Report on Form 10-Q only. In each case, actual results may differ materially from such forward-looking information. We can give no assurance that such expectations or forward-looking statements will prove to be correct. An occurrence of, or any material adverse change in, one or more of the risk factors or risks and uncertainties referred to in this Quarterly Report on Form 10-Q or included in our other public disclosures or our other periodic reports or other documents or filings filed with or furnished to the U.S. Securities and Exchange Commission (the “SEC”) could materially and adversely affect our business, prospects, financial condition, and results of operations. Except as required by law, we do not undertake or plan to update or revise any such forward-looking statements to reflect actual results, changes in plans, assumptions, estimates or projections or other circumstances affecting such forward-looking statements occurring after the date of this Quarterly Report on Form 10-Q, even if such results, changes, or circumstances make it clear that any forward-looking information will not be realized. Any public statements or disclosures by us following this Quarterly Report on Form 10-Q that modify or impact any of the forward-looking statements contained in this Quarterly Report on Form 10-Q will be deemed to modify or supersede such statements in this Quarterly Report on Form 10-Q.

This Quarterly Report on Form 10-Q may include market data and certain industry data and forecasts, which we may obtain from internal company surveys, market research, consultant surveys, publicly available information, reports of governmental agencies and industry publications, articles, and surveys. Industry surveys, publications, consultant surveys, and forecasts generally state that the information contained therein has been obtained from sources believed to be reliable, but the accuracy and completeness of such information is not guaranteed. While we believe that such studies and publications are reliable, we have not independently verified market and industry data from third-party sources.

References to Aditxt, Inc.

Throughout this Quarterly Report on Form 10-Q, the “Company,” “Aditxt,” “we,” “us,” and “our” refers to ~~Aditx Therapeutics,~~Aditxt, Inc. and “our board of directors” refers to the board of directors of ~~Aditx Therapeutics,~~Aditxt, Inc.

~~-ii-~~

iii

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

~~ADITX THERAPEUTICS,~~

ADITXT, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

June 30, December 31,
2020 2019

ASSETS

CURRENT ASSETS:
Cash $ 49,925 $ 4,090
Prepaid expenses 25,083 -

TOTAL CURRENT ASSETS 75,008 4,090

Deferred offering costs 542,581 119,442

TOTAL ASSETS $ 617,589 $ 123,532

LIABILITIES AND STOCKHOLDERS' DEFICIT

CURRENT LIABILITIES:
Accounts payable and accrued expenses $ 2,268,581 $ 1,847,458
Accrued compensation to related parties 1,220,629 962,651
Notes payable - related party 10,000 10,000
Notes payable, net of discount 830,600 155,600

TOTAL CURRENT LIABILITIES 4,329,810 2,975,709

TOTAL LIABILITIES 4,329,810 2,975,709

COMMITMENTS AND CONTINGENCIES

STOCKHOLDERS’ DEFICIT
Preferred stock, $0.001 par value, 3,000,000 shares authorized, zero shares issued and outstanding, respectively - -
Common stock, $0.001 par value, 27,000,000 shares authorized, 4,069,115 and 3,915,900 shares issued and 3,968,312 and 3,821,087 shares outstanding, respectively 4,069 3,916
Treasury stock, 100,803 and 94,813 shares, respectively (201,605 ) (189,625 )
Additional paid-in capital 9,938,946 9,063,483
Accumulated deficit (13,453,631 ) (11,729,951 )
TOTAL STOCKHOLDERS' DEFICIT (3,712,221 ) (2,852,177 )

TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT $ 617,589 $ 123,532
September 30, December 31,
2023 2022
ASSETS
CURRENT ASSETS:
Cash $ 1,651,354 $ 2,768,640
Accounts receivable, net 362,708 527,961
Inventory 858,106 950,093
Prepaid expenses 555,631 496,869
TOTAL CURRENT ASSETS 3,427,799 4,743,563

Fixed assets, net 2,003,859 2,318,863
Intangible assets, net 26,750 107,000
Deposits 312,265 355,366
Right of use asset - long term 2,454,886 3,160,457
Deferred issuance costs - 50,000
TOTAL ASSETS $ 8,225,559 $ 10,735,249

LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)
CURRENT LIABILITIES:
Accounts payable and accrued expenses $ 4,224,425 $ 1,958,502
Notes payable, net of discount 4,020,055 -
Financing on fixed assets 147,823 409,983
Deferred rent 169,633 188,581
Lease liability - current 1,081,377 1,086,658
Settlement liability 1,600,000 -
TOTAL CURRENT LIABILITIES 11,243,313 3,643,724

Lease liability - long term 1,203,876 1,885,218

TOTAL LIABILITIES 12,447,189 5,528,942

STOCKHOLDERS’ EQUITY (DEFICIT)
Preferred stock, $0.001 par value, 3,000,000 shares authorized, zero shares issued and outstanding, respectively - -
Series B Preferred stock, $0.001 par value, 1 share authorized, zero and zero shares issued and outstanding, respectively - -
Series C Preferred stock, $0.001 par value, 1 share authorized, zero and zero shares issued and outstanding, respectively - -
Common stock, $0.001 par value, 100,000,000 shares authorized, 367,902 and 107,698 shares issued and 367,851 and 107,647 shares outstanding, respectively 368 108
Treasury stock, 51 and 51 shares, respectively (201,605 ) (201,605 )
Additional paid-in capital 112,599,764 100,448,166
Accumulated deficit (116,620,157 ) (95,040,362 )
TOTAL STOCKHOLDERS’ EQUITY (DEFICIT) (4,221,630 ) 5,206,307

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) $ 8,225,559 $ 10,735,249
See accompanying notes to the condensed consolidated financial statements.
~~-1-~~
1

~~ADITX THERAPEUTICS,~~
ADITXT, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
Three Months
Ended Three Months
Ended Six Months
Ended Six Months
Ended
June 30,
2020 June 30,
2019 June 30,
2020 June 30,
2019

OPERATING EXPENSES
General and administrative expenses, includes $160,329, $2,098,759, $689,766 and $2,822,367 in stock-based compensation 367,338 2,511,438 $ 1,223,765 $ 3,711,221
Research and development, includes $0, $0, $0 and $0 in stock-based compensation 28,294 43,978 228,665 88,846
Sales and marketing, includes $0, $0, $0 and $0 in stock-based compensation 2,848 109 2,848 147
Total Operating Expenses 398,480 2,555,525 1,455,278 3,800,214

NET LOSS FROM OPERATIONS (398,480 ) (2,555,525 ) (1,455,278 ) (3,800,214 )

OTHER INCOME (EXPENSE)
Interest expense (448 ) (448 ) (902 ) (1,027 )
Gain on forgiveness of debt - - 32,500 45,000
Amortization of debt discount (135,389 ) - (300,000 ) -
Total Other Income (Expense) (135,837 ) (448 ) (268,402 ) 43,973
Net loss before income taxes (534,317 ) (2,555,973 ) (1,723,680 ) (3,756,241 )
Income tax provision - - - -

NET LOSS $ (534,317 ) $ (2,555,973 ) $ (1,723,680 ) $ (3,756,241 )

Net loss per share - basic and diluted $ (0.14 ) $ (0.67 ) $ (0.44 ) $ (0.98 )

Weighted average number of shares outstanding during the period - basic and diluted 3,929,205 3,842,967 3,917,891 3,821,278
Three Months
Ended Three Months
Ended Nine Months
Ended Nine Months
Ended
September 30,
2023 September 30,
2022 September 30,
2023 September 30,
2022
REVENUE
Sales $ 124,486 $ 323,125 $ 563,879 $ 748,119
Cost of goods sold 106,922 233,684 470,969 596,613
Gross Profit 17,564 89,441 92,910 151,506

OPERATING EXPENSES
General and administrative expenses $103,031, $461,492, $484,502, and $1,288,829 in stock-based compensation, respectively 7,169,863 3,919,618 15,209,789 12,332,728
Research and development, includes $49,209, $170,066, $165,382, and $473,593 in stock-based compensation, respectively 898,724 1,570,540 2,771,100 4,186,842
Sales and marketing $1,752, $0, $6,787, and $754,699 in stock-based compensation, respectively 44,186 (8,553 ) 223,562 911,988
Total operating expenses 8,112,773 5,481,605 18,204,451 17,431,558

NET LOSS FROM OPERATIONS (8,095,209 ) (5,392,164 ) (18,111,541 ) (17,280,052 )

OTHER EXPENSE
Interest expense (906,104 ) (645,381 ) (2,389,627 ) (742,701 )
Interest income 367 10,084 9,784 30,131
Other income - - - 58,960
Amortization of debt discount (744,956 ) (1,530,102 ) (921,242 ) (1,533,048 )
Total other expense (1,650,693 ) (2,165,399 ) (3,301,085 ) (2,186,658 )

Net loss before income taxes (9,745,902 ) (7,557,563 ) (21,412,626 ) (19,466,710 )
Income tax provision - - - -

NET LOSS $ (9,745,902 ) $ (7,557,563 ) $ (21,412,626 ) $ (19,466,710 )

Implied Dividends (167,169 ) - (167,169 ) -

NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS $ (9,913,071 ) $ (7,557,563 ) $ (21,579,795 ) $ (19,466,710 )

Net loss per share - basic and diluted $ (48.77 ) $ (210.93 ) $ (136.94 ) $ (720.54 )

Weighted average number of shares outstanding during the period - basic and diluted 203,247 35,829 157,584 27,017
See accompanying notes to the condensed consolidated financial statements.
~~-2-~~
2

~~ADITX THERAPEUTICS,~~
ADITXT, INC.
CONDENSED CONSOLIDATED STATEMENTS OF ~~STOCKHOLDERS' DEFICIT~~STOCKHOLDERS’ EQUITY (DEFICIT)
~~SIX~~THREE AND NINE MONTHS ENDED ~~JUNE~~SEPTEMBER 30, ~~2020~~2023 AND ~~2019~~2022
(Unaudited)

Additional Total
Common Treasury Paid-in Accumulated Stockholders'
Shares Par Shares Capital Deficit Deficit

Balance December 31, 2019 3,821,087 $ 3,916 $ (189,625 ) $ 9,063,483 $ (11,729,951 ) $ (2,852,177 )

Issuance of shares for services 104,750 105 - 418,895 - 419,000

Stock option and warrant compensation - - - 110,437 - 110,437

Treasury stock (5,990 ) - (11,980 ) - - (11,980 )

Net loss - - - - (1,189,363 ) (1,189,363 )

Balance March 31, 2020 (unaudited) 3,919,847 $ 4,021 $ (201,605 ) $ 9,592,815 $ (12,919,314 ) $ (3,524,083 )

Exercise of warrants 30,975 31 - 185,819 - 185,850

Stock option and warrant compensation - - - 77,138 - 77,138

Issuance of shares for services 17,500 18 - 83,174 - 83,192

Adjustment to Common Shares due to reverse stock split (10 ) (1 ) - - - (1 )

Net loss - - - - (534,317 ) (534,317 )

Balance June 30, 2020 (unaudited) 3,968,312 $ 4,069 $ (201,605 ) $ 9,938,946 $ (13,453,631 ) $ (3,712,221 )

Preferred
Shares
Outstanding Preferred
Shares
Par Preferred B
Shares
Outstanding Preferred B
Shares
Par Preferred C
Shares
Outstanding   Preferred C
Shares
Par Common
Shares
Outstanding Common
Shares
Par Treasury
Stock Additional
Paid-in
Capital Accumulated
Deficit Total
Stockholders’
Equity
(Deficit)
Balance December 31, 2022 - $ - - $ - - $ - 107,647 $ 108 $ (201,605 ) $ 100,448,166 $ (95,040,362 ) $ 5,206,307

Stock option and warrant compensation - - - - - - - - - 59,964 - 59,964

Restricted stock unit compensation - - - - - - - - - 111,187 - 111,187

Issuance of shares for vested restricted stock units - - - - - - 44 1 - (1 ) - -

Sale of common stock 8,463 9 - 507,007 - 507,016

Issuance of shares for services - - - - - - 4,675 5 - 168,295 - 168,300

Net loss - - - - - - - - - - (5,984,706 ) (5,984,706 )

Balance March 31, 2023 - $ - - $ - - $ - 120,829 $ 123 $ (201,605 ) $ 101,294,618 $ (101,025,068 ) $ 68,068

Stock option and warrant compensation - - - - - - - - - 59,964 - 59,964

Restricted stock unit compensation - - - - - - - - - 103,264 - 103,264

Issuance of shares for vested restricted stock units - - - - - - 42 1 - (1 ) - -

Warrants issued for cash, net of issuance costs - - - - - - - - - 1,581,467 - 1,581,467

Exercise of warrants - - - - - - 48,184 49 - (49 ) - -

Net loss - - - - - - - - - - (5,682,018 ) (5,682,018 )

Balance June 30, 2023 - $ - - $ - - $ - 169,055 $ 173 $ (201,605 ) $ 103,039,263 $ (106,707,086 ) $ (3,869,255 )

Stock option compensation - - - - - - - - - 59,964 - 59,964

Restricted stock unit compensation - - - - - - - - - 94,028 - 94,028

Issuance of restricted stock units for compensation - - - - - - 71 - - - - -

Sale of Series C Preferred shares to related party - - - - 1 - - - - 1,000 - 1,000

Issuance of shares for debt issuance costs - - - - - - 21,184 22 - 271,984 - 272,006

Issuance of warrants for offering, net of issuance costs - - - - - - - - - 8,966,400 - 8,966,400

Exercise of warrants - - - - - - 136,190 137 - (8 ) - 129

Rounding from reverse stock split - - - - - - 41,351 36 - (36 ) - -

Modification of warrants - - - - - - - - - 167,169 (167,169 ) -

Redemption of Series C Preferred shares to related party - - - - (1 ) - - - - - - -
Net loss - - - - - - - - - - (9,745,902 ) (9,745,902 )

Balance September 30, 2023 - $ - - $    -
-
$ - 367,851 $ 368 $ (201,605 ) $ 112,599,764 $ (116,620,157 ) $ (4,221,630 )
Additional Total
Common Treasury Paid-in Accumulated Stockholders'
Shares Par Shares Capital Deficit Deficit

Balance December 31, 2018 3,763,925 $ 3,764 $ - $ 4,361,725 $ (5,902,223 ) $ (1,536,734 )

Issuance of shares for cash, net of issuance costs 60,250 60 - 198,594 - 198,654

Issuance of shares for services and licenses 13,000 13 - 51,987 - 52,000

Stock option and warrant compensation - - - 671,608 - 671,608

Net loss - - - - (1,200,268 ) (1,200,268 )

Balance March 31, 2019 (unaudited) 3,837,175 $ 3,837 $ - $ 5,283,914 $ (7,102,491 ) $ (1,814,740 )

Issuance of shares for cash, net of issuance costs 11,250 11 - 36,799 - 36,810

Issuance of shares for services and licenses 7,500 8 - 29,992 - 30,000

Stock option and warrant compensation - - - 2,068,759 - 2,068,759

Treasury stock (45,356 ) - (90,712 ) - - (90,712 )

Net loss - - - - (2,555,973 ) (2,555,973 )

Balance June 30, 2019 (unaudited) 3,810,569 $ 3,856 $ (90,712 ) $ 7,419,464 $ (9,658,464 ) $ (2,325,856 )

See accompanying notes to the condensed        consolidated financial statements.
~~-3-~~
3

~~ADITX THERAPEUTICS,~~ADITXT, INC.
CONDENSED CONSOLIDATED STATEMENTS OF ~~CASH FLOWS~~STOCKHOLDERS’ EQUITY (DEFICIT)
THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022
(Unaudited)
Six
Months Ended Six
Months Ended
June 30,
2020 June 30,
2019
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss $ (1,723,680 ) $ (3,756,241 )
Adjustments to reconcile net loss to net cash used in operating activities
Stock-based compensation 689,766 2,822,367
Amortization of debt discount 300,000 -
Changes in operating assets and liabilities:
Prepaid expenses (25,083 ) -
Accounts payable and accrued expenses 95,429 365,653
Accrued compensation to related parties 257,978 259,014
Net cash used in operating activities (405,590 ) (309,207 )

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from notes payable - related party - 10,000
Proceeds from notes payable 375,000 -
Repayments of notes payable - related party - (42,502 )
Repayments of notes payable - (5,000 )
Common stock issued for cash, net of issuance costs - 235,464
Deferred offering costs (109,425 ) -
Exercise of warrants 185,850 -
Net cash provided by financing activities 451,425 197,962

NET INCREASE (DECREASE) IN CASH 45,835 (111,245 )

CASH AT BEGINNING OF PERIOD 4,090 115,709

CASH AT END OF PERIOD $ 49,925 $ 4,464

Supplemental cash flow information:
Cash paid for income taxes $ - $ -
Cash paid for interest expense $ - $ -

NON-CASH INVESTING AND FINANCING ACTIVITIES:
Liabilities assumed for common stock $ 11,980 $ 90,712
Deferred offering costs accrued and payable $ 313,714 $ -
Original issuance discount on notes payable $ 300,000 $ -
Preferred
Shares
Outstanding Preferred
Shares
Par Preferred B
Shares
Outstanding Preferred B
Shares
Par Preferred C
Shares
Outstanding Preferred C
Shares
Par Common
Shares
Outstanding Common
Shares
Par Treasury
Stock Additional
Paid-in
Capital Accumulated
Deficit Total
Stockholders’
Equity
(Deficit)
Balance December 31, 2021 - $ - - $ - - $ - 22,220 $ 22 $ (201,605 ) $ 77,735,165 $ (67,352,809 ) $ 10,180,773

Stock option and warrant compensation - - - - - - - - - 219,885 - 219,885

Issuance of shares for vested restricted stock units - - - - - - 144 1 - (1 ) - -

Restricted stock unit compensation - - - - - - - - - 377,671 - 377,671

Issuance of shares for services - - - - - - 5 1 - 3,718 - 3,719

Net loss - - - - - - - - - - (6,059,141 ) (6,059,141 )

Balance March 31, 2022 - $ - - $ - - $ - 22,369 $ 24 $ (201,605 ) $ 78,336,438 $ (73,411,950 ) $ 4,722,907

Stock option and warrant compensation - - - - - - - - - 724,584 - 724,584

Issuance of restricted stock units for compensation - - - - - - 69 1 - (1 ) - -

Restricted stock unit compensation - - - - - - - - - 309,704 - 309,704

Exercise of warrants, modification of warrants, and issuance of warrants - - - - - - 4,486 5 - 1,203,764 - 1,203,769

Issuance of shares for services - - - - - - 768 1 - 249,999 - 250,000

Net loss - - - - - - - - - - (5,850,006 ) (5,850,006 )

Balance June 30, 2022 - $ - - $ - - $ - 27,692 $ 31 $ (201,605 ) $ 80,824,488 $ (79,261,956 ) $ 1,360,958

Stock option and warrant compensation - - - - - - - - - 338,439 - 338,439

Restricted stock unit compensation - - - - - - 166 1 - 293,118 - 293,119

Sale of Series B Preferred shares to related party - - 1 - - - - - - 20,000 - 20,000

Redemption of Series B Preferred shares to related party - - (1 ) - - - - - - (20,000 ) - (20,000 )

Shares issued as inducement on loans, net of issuance costs - - - - - - 1,195 2 - 146,520 - 146,522

Warrants issued with loans - - - - - - - - - 878,622 - 878,622

Modification of warrants - - - - - - - - - 8,619 (8,619 ) -

Issuance of shares for debt issuance costs - - - - - - 262 1 - 96,029 - 96,030

Exercise of warrants - - - - - - 33,423 34 - (34 ) - -

Issuance of shares and warrants for offering, net of issuance costs - - - - - - 30,609 31 - 17,232,524 - 17,232,555

Issuance of shares for services - - - - - - (360 ) (1 ) - 1 - -

Issuance costs related to exercise of warrants, modification of warrants, and issuance of warrants - - - - - - - - - (94,195 ) - (94,195 )

Rounding from reverse stock split - - - - - - 301 (6 ) - (7 ) - (13 )

Net loss - - - - - - - - - - (7,557,563 ) (7,557,563 )

Balance September 30, 2022 - $ - - $ - - $ - 93,288 $ 93 $ (201,605 ) $ 99,724,124 $ (86,828,138 ) $ 12,694,474
See accompanying notes to the condensed consolidated financial statements.
~~-4-~~
4

ADITXT, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
Nine Months
Ended Nine Months
Ended
September 30,
2023 September 30,
2022
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss $ (21,412,626 ) $ (19,466,710 )
Adjustments to reconcile net loss to net cash used in operating activities
Stock-based compensation 656,671 2,517,121
Depreciation expense 329,411 296,685
Amortization of intangible assets 80,250 80,250
Amortization of debt discount 921,242 1,533,048
Changes in operating assets and liabilities:
Accounts receivable 165,253 (229,315 )
Prepaid expenses (58,762 ) (18,864 )
Deposits 43,101 (572,966 )
Inventory 91,987 (947,729 )
Accounts payable and accrued expenses 2,315,923 1,136,448
Settlement liability 1,600,000 -
Net cash used in operating activities (15,267,550 ) (15,672,032 )

CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of fixed assets (14,407 ) (278,256 )
Tenant improvement allowance receivable - (87,934 )
Notes receivable and accrued interest - (55,454 )
Net cash used in investing activities (14,407 ) (421,644 )

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from notes - related party 687,523 80,000
Proceeds from note payable 5,962,865 3,138,888
Discount on note payable from offering costs - (411,887 )
Repayments of note payable - related party (687,523 ) -
Repayment of note payable (2,592,046 ) (3,138,888 )
Sale of Series B Preferred shares to related party - 20,000
Common stock issued for cash, net of issuance costs 10,547,867 -
Warrants issued for cash, net of issuance costs 507,016 -
Common stock and warrants issued for cash, net of issuance costs - 17,232,555
Sale of Series C Preferred shares to related party 1,000 -
Exercise of warrants, modification of warrants, and issuance of warrants 129 1,109,574
Payments on financing on fixed asset (262,160 ) (563,751 )
Net cash provided by financing activities 14,164,671 17,466,491

NET INCREASE (DECREASE) IN CASH (1,117,286 ) 1,372,815

CASH AT BEGINNING OF YEAR 2,768,640 7,872,061

CASH AT END OF PERIOD $ 1,651,354 $ 9,244,876

Supplemental cash flow information:
Cash paid for income taxes $ - $ -
Cash paid for interest expense $ 1,190,332 $ 740,301

Debt Discount from warrants issued with convertible note payable $ - $ 878,622
Debt Discount from shares issued as inducement for note payable $ 272,006 $ 174,522
Shares issued for debt offering costs $ - $ 96,030
Redemption of Series B Preferred shares to related party $ - $ 20,000
Warrant modification $
167,169
$ 8,619
See accompanying notes to the condensed consolidated financial statements.
5

~~ADITX THERAPEUTICS,~~
ADITXT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)
NOTE 1 – ORGANIZATION AND NATURE OF BUSINESS
Company Background
~~Aditx Therapeutics, Inc. (“Aditxt” or the “Company”) was incorporated on September 28, 2017 under the laws of the State of Delaware. The Company is~~Overview
We are a ~~pre-clinical stage, life sciences~~biotech innovation company with a mission of prolonging life and enhancing its quality by improving the health of the immune system. ~~Aditxt is~~We are an innovation company developing and commercializing technologies ~~specifically focused~~with a focus on ~~improving the health of~~monitoring and modulating the immune ~~system through~~system. Our immune reprogramming ~~and monitoring. Aditxt’s immune reprogramming technology is~~technologies are currently at the pre-clinical stage and isare designed to retrain the immune system to induce tolerance with an objective of addressing rejection of transplanted organs, autoimmune diseases, and allergies. ~~Aditxt’s~~Our immune monitoring ~~technology is~~technologies are designed to provide a personalized comprehensive profile of the immune system and ~~the Company plans~~we plan to utilize them in ~~its~~our upcoming reprogramming clinical trials to monitor subjects’ immune response before, during and after drug administration. ~~Aditxt is also evaluating plans~~
On January 1, 2023, the Company formed Adimune, Inc., a Delaware wholly owned subsidiary.
On January 1, 2023, the Company formed Pearsanta, Inc., a Delaware wholly owned subsidiary.
On April 13, 2023, the Company formed Adivir, Inc., a Delaware wholly owned subsidiary.
Reverse Stock Split
On September 13, 2022, the Company effectuated a 1 for 50 reverse stock split (the “2022 Reverse Split”). The Company’s stock began trading on a split-adjusted basis effective on the Nasdaq Stock Market on September 14, 2022. There was no change to ~~obtain approval from~~ the ~~U.S. Food and Drug Administration (FDA)~~number of authorized shares of the Company’s common stock.
On August 17, 2023, the Company effectuated a 1 for 40 reverse stock split (the “2023 Reverse Split”). The Company’s stock began trading on a split-adjusted basis effective on the Nasdaq Stock Market on August 18, 2023. There was no change to the number of authorized shares of the Company’s common stock. All share amounts referenced in this ~~monitoring tool’s use as a clinical assay.~~report are adjusted to reflect the 2023 Reverse Split.
Offerings
On ~~July 2, 2020,~~August 31, 2021, the Company completed ~~its initial public~~a registered direct offering (“~~IPO”~~August 2021 Offering”). In connection therewith, the Company issued ~~1,226,668 Units (the “Units”), excluding the underwriters’ option to cover overallotments,~~2,292 shares of common stock, at ~~an offering~~a purchase price of ~~$9.00~~$4,800.00 per ~~Unit,~~share, resulting in gross proceeds of approximately $11.0 million. ~~The Units~~In a concurrent private placement, the Company issued ~~in the IPO consisted of one share of common stock, one Series A warrant, and one Series B warrant.~~warrants to purchase up to 2,292 shares. The ~~Series A~~ warrants have an exercise price of ~~$9.00~~$5,060.00 per share and are exercisable for a ~~term~~five-year period commencing months from the date of ~~5 years.~~issuance. The ~~Series B~~ warrants ~~have~~exercise price was subsequently repriced to $3,000.00. In addition, the Company issued a warrant to the placement agent to purchase up to 115 shares of common stock at an exercise price of ~~$11.25, a term~~$6,000.00 per share.
On October 18, 2021, the Company entered into an underwriting agreement with Revere Securities LLC, relating to the public offering (the “October 2021 Offering”) of ~~5 years and contain a cashless exercise option upon certain criteria being met. Subsequent to quarter end, substantially all~~1,417 shares of the ~~Series B~~Company’s common stock (the “Shares”) by the Company. The Shares were offered, issued, and sold at a price to the public of $3,000.00 per share under a prospectus supplement and accompanying prospectus filed with the SEC pursuant to an effective shelf registration statement filed with the SEC on Form S-3 (File No. 333-257645), which was declared effective by the SEC on July 13, 2021. The October 2021 Offering closed on October 20, 2021 for gross proceeds of $4.25 million. The Company utilized a portion of the proceeds, net of underwriting discounts of approximately $3.91 million from the October 2021 Offering to fund certain obligations of the Company.
6
On December 6, 2021, the Company completed a public offering for net proceeds of $16.0 million (the “December 2021 Offering”). As part of the December 2021 Offering, we issued 4,123 units consisting of shares of the Company’s common stock and warrant to purchase shares of the Company’s common stock and 4,164 prefunded warrants. The warrant issued as part of the units had an exercise price of $2,300.00 and the prefunded warrants ~~issued~~had an exercise price of $0.04. On June 15, 2022, the Company entered an agreement with a holder of certain warrants in the ~~IPO have been exercised~~December 2021 Offering. (See Note 10)
On September 20, 2022, the Company completed a public offering for net proceeds of $17.2 million (the “September 2022 Offering”). As part of the September 2022 Offering, we issued 30,608 of shares of the Company’s common stock, pre-funded warrants to purchase 52,725 shares of common stock, and warrants to purchase 83,333 shares of the Company’s common stock. The warrants had an exercise price of $240.00 and the pre-funded warrants had an exercise price of $0.04.
On April 20, 2023, the Company entered into a securities purchase agreement (the “April Purchase Agreement”) with an institutional investor, pursuant to which the Company agreed to sell to such investor pre-funded warrants (the “April Pre-Funded Warrants”) to purchase up to 39,634 shares of common stock of the Company (the “Common Stock”) at a ~~cashless provision therein.~~purchase price of $48.76 per April Pre-Funded Warrant. The April Pre-Funded Warrants (and shares of common stock underlying the April Pre-Funded Warrants) were offered by the Company pursuant to its shelf registration statement on Form S-3 (File No. 333-257645), which was declared effective by the Securities and Exchange Commission on July 13, 2021. Concurrently with the sale of the April Pre-Funded Warrants, pursuant to the Purchase Agreement in a concurrent private placement, for each April Pre-Funded Warrant purchased by the investor, such investor received from the Company an unregistered warrant (the “Warrant”) to purchase two shares of Common Stock. The warrants have an exercise price of $34.40 per share, and are exercisable for a three year period. In addition, the Company issued a warrant to the placement agent to purchase up to 2,378 shares of common stock at an exercise price of $61.00 per share. The closing of the sales of these securities under the April Purchase Agreement took place on April 24, 2023. The gross proceeds from the offering were approximately $1.9 million, prior to deducting placement agent’s fees and other offering expenses payable by the Company.
On August 31, 2023, the “Company entered into a securities purchase agreement (the “August Purchase Agreement”) with an institutional investor for the issuance and sale in a private placement (the “Private Placement”) of (i) pre-funded warrants (the “August Pre-Funded Warrants”) to purchase up to 1,000,000 shares of the Company’s common stock at an exercise price of $0.001 per share, and (ii) warrants (the “Common Warrants”) to purchase up to 1,000,000 shares of the Company’s Common Stock at an exercise price of $10.00 per share. The Private Placement closed on September 6, 2023. The net proceeds to the Company from the Private Placement were approximately $9 million, after deducting placement agent fees and expenses and estimated offering expenses payable by the Company. The Company intends to use the net proceeds received from the Private Placement for (i) the payment of approximately $3.1 million in outstanding obligations, (ii) the repayment of approximately $0.4 million of outstanding debt, and (iii) the balance for continuing operating expenses and working capital.
Risks and Uncertainties
The Company has a limited operating history and ~~has not generated~~is in the very early stages of generating revenue from intended operations. The Company’s business and operations are sensitive to general business and economic conditions in the U.S. and worldwide along with local, state, and federal governmental policy decisions. A host of factors beyond the Company’s control could cause fluctuations in these conditions. Adverse conditions may include: changes in the biotechnology regulatory environment, technological advances that render our technologies obsolete, availability of resources for clinical trials, acceptance of technologies into the medical community, and competition from larger, more well-funded companies. These adverse conditions could affect the Company’s financial condition and the results of its operations.
On January 30, 2020, the World Health Organization declared the COVID-19 novel coronavirus outbreak a “Public Health Emergency of International Concern” and on March 10, 2020, declared it to be a pandemic. Actions taken around the world to help mitigate the spread of the coronavirus ~~include~~included restrictions on travel, and quarantines in certain areas, and forced closures for certain types of public places and businesses. The COVID-19 coronavirus and actions taken to mitigate it have had ~~and are expected to continue to have~~ an adverse impact on the economies and financial markets of many countries, including the geographical area in which the Company operates. While it is unknown how long these conditions will last and what the financial impact will be to the Company, it is reasonably possible that future capital ~~raise~~raising efforts and additional development of our technologies may be negatively affected.
7
NOTE 2 – GOING CONCERN ANALYSIS
Management Plans
The Company was incorporated on September 28, 2017 and has not generated significant revenues to date. During the ~~six~~nine months ended ~~June~~September 30, ~~2020,~~2023, the Company had a net loss of ~~$1,723,680~~$21,412,626 and negative cash flow from operating activities of ~~$49,925. However, subsequent~~$15,267,550. As of September 30, 2023, the Company’s cash balance was $1,651,354.
As of September 30, 2023, the Company had approximately $4.8 million of availability to sell under its shelf registration statement on Form S-3. Upon the filing of the Company’s annual report on Form 10-K on April 17, 2023, the Company’s aggregate market value of the voting and non-voting equity held by non-affiliates was below $75.0 million. As a result, the maximum amount that the Company can sell under its shelf registration statement on Form S-3 during any 12 month period is equal to one-third of the aggregate market value of the voting and non-voting equity held by non-affiliates of the Company.
On May 23, 2023, we received written notice from Nasdaq that, based upon the stockholders equity reported by the Company in its Form 10-Q for the period ended March 31, 2023, and as of March 31, 2023, the Company was no longer in compliance with Nasdaq Listing Rule 5550(b)(1), which requires a company to maintain a minimum of $2,500,000 in stockholders’ equity, a market value of listed securities of at least $35 million, or net income from continuing operations of $500,000 in the most recently completed fiscal year or in two of the three most recently completed fiscal years (the “Continued Listing Requirements”). The May notification letter further provided that the Company had 45 calendar days, or until July 7, 2023, to submit a plan to regain compliance and if the plan is accepted by Nasdaq, an extension of up to 180 calendar days, or until November 19, 2023 to evidence compliance.
On June 22, 2023, we received a letter from Nasdaq notifying the Company that it has failed to maintain compliance with the minimum bid price rule in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Rule”) as the closing price of Company’s common stock had remained below $1.00 for over 30 ~~2020,~~consecutive trading days. On June 29, 2023, we submitted an appeal to Nasdaq, which stayed the delisting and suspension of our securities pending the decision of the Nasdaq Hearings Panel (the “Panel”). The hearing was held on August 31, 2023, which represented the tenth trading day that the closing of the Company’s common stock was above $1.00 per share. At the hearing, the Company also presented its plans to regain compliance with the Equity Rule to the Panel.
In addition, on September 15, 2023, the Company received ~~approximately $9.5 million in cash as net proceeds~~a written notice from Nasdaq that it no longer met the ~~IPO (See Note 1)~~minimum 500,000 publicly-held shares requirement for The Nasdaq Capital Market and it no longer complies with Nasdaq Listing Rule 5550(a)(4) (the “Public Float Rule”). The ~~Company~~September notification letter stated that the Panel will ~~be conducting medical research and development, and~~consider this matter in their decision regarding the ~~time at which~~Company’s continued listing on The Nasdaq Capital Market.
On September 29, 2023, the Company ~~will begin generating revenue is unknown. The Company believes, however,~~received a written notice from Nasdaq that the ~~funds raised~~Panel had granted the Company an exception through December 26, 2023, to allow the Company to complete its compliance with the Equity Rule. The October notification letter also confirmed that the Company had demonstrated compliance with the Minimum Bid Price Rule and granted the Company an exception through December 26, 2023 to allow the Company to demonstrate compliance with the Public Float Rule.
If we are delisted from Nasdaq, but obtain a substitute listing for our common stock, it will likely be on a market with less liquidity, and therefore experience potentially more price volatility than experienced on Nasdaq. Stockholders may not be able to sell their shares of common stock on any such substitute market in the quantities, at the times, or at the prices that could potentially be available on a more liquid trading market. As a result of these factors, if our common stock is delisted from Nasdaq, the value and liquidity of our common stock, warrants and pre-funded warrants would likely be significantly adversely affected. A delisting of our common stock from Nasdaq could also adversely affect our ability to obtain financing for our operations and/or result in a loss of confidence by ~~the IPO will be sufficient to fund~~investors, employees and/or business partners.
In addition, factors such as stock price, volatility, trading volume, market conditions, demand and regulatory requirements may adversely affect the Company’s ~~operation for at least the next 12 months.~~ability to raise capital in an efficient manner. Because of these factors, the Company believes that this ~~alleviates issues in connection~~creates substantial doubt with the Company’s ability to continue as a going concern.
8
In addition to the shelf registration, the Company has the ability to raise capital from equity or debt through private placements or public offerings pursuant to a registration statement on Form S-1. We may also secure loans from related parties.
The ~~accompanying~~ financial statements ~~have been prepared assuming that the Company will continue as a going concern.~~
~~The financial statements~~included in this report do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the matters discussed herein. ~~While we believe in the viability of our strategy to generate sufficient revenue, control costs and raise additional funds when necessary, there can be no assurances to that effect.~~ The Company’s ability to continue as a going concern is dependent upon the ability to complete clinical studies and implement the business plan, generate sufficient revenues and to control operating expenses.
In addition, the Company is consistently focused on raising capital, strategic acquisitions and alliances, and other initiatives to strengthen the Company.
~~-5-~~
NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and the rules and regulations of the Securities and Exchange Commission (“SEC”). In the opinion of the Company’s management, the accompanying condensed consolidated financial statements reflect all adjustments, consisting of normal, recurring adjustments, considered necessary for a fair presentation of the results for the interim periods ended ~~June~~September 30, ~~2020~~2023 and ~~2019.~~September 30, 2022. Although management believes that the disclosures in these unaudited condensed consolidated financial statements are adequate to make the information presented not misleading, certain information and footnote disclosures normally included in condensed consolidated financial statements that have been prepared in accordance U.S. GAAP have been or omitted pursuant to the rules and regulations of the SEC.
The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the Company’s financial statements and notes related thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, ~~2019, which contain the audited financial statements and notes thereto, included in the Company’s Prospectus, dated June 29, 2020,~~2022, filed with the SEC ~~pursuant to Rule 424(b).~~on April 17, 2023. The interim results for the ~~six~~nine months ended ~~June~~September 30, ~~2020~~2023 are not necessarily indicative of the results to be expected for the year ended December 31, ~~2020~~2023 or for any future interim periods.
Principles of Consolidation
The unaudited consolidated financial statements include the accounts of Aditxt, Inc., and its wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated in the condensed consolidated financial statements.
Use of Estimates
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense during the reporting period. Actual results could differ from those estimates. Significant estimates underlying the financial statements include the collectability of notes receivable, collectability and reserve on accounts receivable, the reserve on insurance billing, and the fair value of stock options and warrants.
Fair Value Measurements and Fair Value of Financial Instruments
The Company adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 820, Fair Value Measurements. ASC Topic 820 clarifies the definition of fair value, prescribes methods for measuring fair value, and establishes a fair value hierarchy to classify the inputs used in measuring fair value as follows:
Level 1 - Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date.
Level 2 - Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data.
Level 3 - Inputs are unobservable inputs which reflect the reporting entity’s own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information.
9

~~Level 1-Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date.~~
Level 2-Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data.
Level 3-Inputs are unobservable inputs which reflect the reporting entity’s own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information.
The Company did not identify any assets or liabilities that are required to be presented on the balance sheets at fair value in accordance with ASC Topic 820.
~~-6-~~
Due to the short-term nature of all financial assets and liabilities, their carrying value approximates their fair value as of the balance sheet dates.
Concentrations of Credit Risk
Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable.
The Company maintains its cash accounts at financial institutions which are insured by the Federal Deposit Insurance Corporation. At times, the Company may have deposits in excess of federally insured limits.
Substantially all the Company’s accounts receivable are with companies in the healthcare industry, individuals, and the U.S. government. However, concentration of credit risk is mitigated due to the Company’s number of customers. In addition, for receivables due from U.S. government agencies, the Company does not believe the receivables represent a credit risk as these are related to healthcare programs funded by the U.S. government and payment is primarily dependent upon submitting the appropriate documentation.
Cash and Cash Equivalents
Cash and cash equivalents include short-term, liquid investments.
Inventory
Inventory consists of laboratory materials and supplies used in laboratory analysis. We capitalize inventory when purchased. Inventory is valued at the lower of cost or net realizable value on a first-in, first-out basis. We periodically perform obsolescence assessments and write off any inventory that is no longer usable.
Fixed Assets
Fixed assets are stated at cost less accumulated depreciation. Cost includes expenditures for furniture, office equipment, laboratory equipment, and other assets. Maintenance and repairs are charged to expense as incurred. When assets are sold, retired, or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is reflected in operations. The costs of fixed assets are depreciated using the straight-line method over the estimated useful lives or lease life of the related assets.
Useful lives assigned to fixed assets are as follows:
Computers Three years to five years
Lab Equipment Seven to ten years
Office Furniture Five to ten years
Other fixed assets Five to ten years
Leasehold Improvements Shorter of estimated useful life or remaining lease term
Intangible Assets
Intangible assets are stated at cost less accumulated amortization. For intangible assets that have finite lives, the assets are amortized using the straight-line method over the estimated useful lives of the related assets. For intangible assets with indefinite lives, the assets are tested periodically for impairment.
10
Accounts Receivable and Allowance for Doubtful Accounts
Accounts receivable are stated at the amount management expects to collect from outstanding balances. The Company ~~considers all highly liquid investments~~generally does not require collateral to support customer receivables. The Company determines if receivables are past due based on days outstanding, and amounts are written off when determined to be uncollectible by management. As of September 30, 2023 and December 31, 2022, there was an allowance for doubtful accounts of zero and $18,634, respectively.
Offering Costs
Offering costs incurred in connection with equity are recorded as a reduction of equity and offering costs incurred in connection with debt are recorded as a reduction of debt as a debt discount.
Revenue Recognition
In accordance with ASC 606 (Revenue From Contracts with Customers), revenue is recognized when a customer obtains control of promised services. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these services. To achieve this core principle, the Company applies the following five steps:
1) Identify the contract with a customer
2) Identify the performance obligations in the contract
3) Determine the transaction price
4) Allocate the transaction price to performance obligations in the contract
5) Recognize revenue when or as the Company satisfies a performance obligation
Revenues reported from services relating to the AditxtScore™ are recognized when the AditxtScore^TMreport is delivered to the customer. The services performed include the analysis of specimens received in the Company’s CLIA laboratory and the generation of results which are then delivered upon completion.
The Company recognizes revenue in the following manner for the following types of customers:
Client Payers:
Client payers include physicians or other entities for which services are billed based on negotiated fee schedules. The Company principally estimates the allowance for credit losses for client payers based on historical collection experience and the period of time the receivable has been outstanding.
Cash Pay:
Customers are billed based on established patient fee schedules or fees negotiated with physicians on behalf of their patients. Collection of billings is subject to credit risk and the ability of the patients to pay.
Insurance:
Reimbursements from healthcare insurers are based on fee for service schedules. Net revenues recognized consist of amounts billed net of contractual allowances for differences between amounts billed and the estimated consideration the Company expects to receive from such payers, collection experience, and the terms of the Company’s contractual arrangements.
11
Leases
Under Topic 842 (Leases), operating lease expense is generally recognized evenly over the term of the lease. The Company has operating leases consisting of office space, laboratory space, and lab equipment.
Leases with an ~~original maturity~~initial term of ~~three~~twelve months or less ~~when purchased to be cash equivalents. As of June 30, 2020 and December 31, 2019, the Company did~~are not ~~have any cash equivalents.~~
~~Offering Costs~~
~~The Company accounts for offering costs in accordance with ASC 340, Other Assets and Deferred Costs. Prior to the completion of an offering, offering costs were capitalized as deferred offering costs~~recorded on the balance sheet. ~~The deferred offering costs are netted against~~We combine the ~~proceeds~~lease and non-lease components in determining the lease liabilities and right of ~~the offering in stockholders’ deficit or the related debt, as applicable. Costs related to unsuccessful offerings are expensed.~~use (“ROU”) assets.
Stock-Based Compensation
The Company accounts for stock-based compensation costs under the provisions of ASC 718, Compensation—Stock Compensation, which requires the measurement and recognition of compensation expense related to the fair value of stock-based compensation awards that are ultimately expected to vest. ~~Stock based~~Stock-based compensation expense recognized includes the compensation cost for all stock-based payments granted to employees, officers, and directors based on the grant date fair value estimated in accordance with the provisions of ASC 718. ~~ASC.~~ASC 718 is also applied to awards modified, repurchased, or cancelled during the periods reported. Stock-based compensation is recognized as expense over the employee’s requisite vesting period and over the nonemployee’s period of providing goods or services.
Patents
The Company incurs fees from patent ~~licenses.~~licenses, which are reflected in research and development expenses, and are expensed as incurred. During the ~~six~~nine months ended ~~June~~September 30, ~~2020~~2023 and ~~2019,~~2022, the Company ~~had a~~incurred patent licensing ~~fee for the patents~~fees of ~~$126,670~~$117,291 and ~~$15,181,~~$256,589, respectively.
Research and Development
We incur research and development costs during the process of researching and developing our technologies and future offerings. ~~Our research and development costs mainly consist of licensing costs.~~ We expense these costs as incurred unless such costs qualify for capitalization under applicable guidance. During the nine months ended September 30, 2023 and 2022, the Company incurred research and development costs of $2,771,100 and $4,186,842, respectively.
Basic and Diluted Net Loss per Common Share
Basic loss per common share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding for each period. Diluted loss per share is computed by dividing the net loss attributable of common stockholders by the weighted average number of shares of common stock outstanding plus the dilutive effect of shares issuable through the common stock equivalents. The weighted-average number of common shares outstanding excludes common stock equivalents because their inclusion would be anti-dilutive. As of ~~June~~September 30, ~~2020, 1,110,000~~2023, 1,127 stock options, 0 unvested restricted stock units, and ~~1,291,503~~2,132,882 warrants were excluded from dilutive earnings per share as their effects were anti-dilutive. As of ~~June~~September 30, ~~2019, 1,102,500~~2022, 1,127 stock options, 264 unvested restricted stock units, and ~~1,077,173~~127,281 warrants were excluded from dilutive earnings per share as their effects were anti-dilutive.
~~-7-~~
Recent Accounting Pronouncements
In February 2016, FASB issued Accounting Standards Update (“ASU”) 2016-02: Leases (Topic 842). The new guidance generally requires an entity to recognize on its balance sheet operating and financing lease liabilities and corresponding right-of-use assets. The standard will be effective for the first interim period within annual reporting periods beginning after December 15, 2018 and early adoption is permitted. The new standard requires a modified retrospective transition for existing leases to each prior reporting period presented. The Company has elected to utilize the extended adoption period available to the Company as an emerging growth company and has not currently adopted this standard. This standard will be effective for the first interim period within annual reporting periods beginning after December 15, 2020. The Company is currently evaluating the impact of the adoption of ASU 2016-02 on its financial position, results of operations and cash flows once adopted.
The FASB issues ASUs to amend the authoritative literature in ASC. There have been several ASUs to date, including those above, that amend the original text of ASC. Management believes that those issued to date either (i) provide supplemental guidance, (ii) are technical corrections, (iii) are not applicable to us or (iv) are not expected to have a significant impact on our financial statements.
12
NOTE 4 – FIXED ASSETS
The Company’s fixed assets include the following on September 30, 2023:
Cost Basis Accumulated
Depreciation Net
Computers $ 378,480 $ (292,655 ) $ 85,825
Lab Equipment 2,585,077 (789,781 ) 1,795,296
Office Furniture 56,656 (12,449 ) 44,207
Other Fixed Assets 8,605 (1,869 ) 6,736
Leasehold Improvements 120,440 (48,645 ) 71,795
Total Fixed Assets $ 3,149,258 $ (1,145,399 ) $ 2,003,859
The Company’s fixed assets include the following on December 31, 2022:
Cost Basis Accumulated
Depreciation Net
Computers $ 376,429 $ (197,907 ) $ 178,522
Lab Equipment 2,572,720 (579,015 ) 1,993,705
Office Furniture 56,656 (8,200 ) 48,456
Other Fixed Assets 8,605 (1,224 ) 7,381
Leasehold Improvements 120,440 (29,641 ) 90,799
Total Fixed Assets $ 3,134,850 $ (815,987 ) $ 2,318,863
Depreciation expense was $109,611 and $99,980 for the three months ended September 30, 2023 and 2022, respectively. Depreciation expense was $329,411 and $296,685 for the nine months ended September 30, 2023 and 2022, respectively. None of the Company’s fixed assets serve as collateral against any loans as of September 30, 2023 and December 31, 2022, other than those subject to the financed asset liability. As of September 30, 2023 and December 31, 2022, the fixed assets that serve as collateral subject to the financed asset liability have a carrying value of $1,316,830 and $1,359,091, respectively.
Financed Assets:
In October 2020, the Company purchased two pieces of lab equipment and financed them for a period of twenty-four months with a monthly payment of $19,487, with an interest rate of 8%. As of September 30, 2023, the Company has one payment in arrears.
In January of 2021, the Company purchased one piece of lab equipment and financed it for a period of twenty-four months with a monthly payment of $9,733, with an interest rate of 8%. As of September 30, 2023, the Company has one payment in arrears.
In March of 2021, the Company purchased five pieces of lab equipment and financed them for a period of twenty-four months with a monthly payment of $37,171, with an interest rate of 8%. As of September 30, 2023, the Company has four payments in arrears.
As of September 30, 2023, all lab equipment financing agreements have matured.
NOTE 5 – INTANGIBLE ASSETS
The Company’s intangible assets include the following on September 30, 2023:
Cost Basis Accumulated
Amortization Net
Proprietary Technology $ 321,000 $ (294,250 ) $ 26,750
Total Intangible Assets $ 321,000 $ (294,250 ) $ 26,750
13
The Company’s intangible assets include the following on December 31, 2022:
Cost Basis Accumulated
Amortization Net
Proprietary Technology $ 321,000 $ (214,000 ) $ 107,000
Total Intangible Assets $ 321,000 $ (214,000 ) $ 107,000
Amortization expense was $26,750 and $26,750 for the three months ended September 30, 2023 and 2022, respectively. Amortization expense was $80,250 and $80,250 for the nine months ended September 30, 2023 and 2022, respectively. None of the Company’s intangible assets serve as collateral against any loans as of September 30, 2023 and December 31, 2022. The Company’s proprietary technology is being amortized over its estimated useful life of three years.
NOTE 46 – RELATED PARTY TRANSACTIONS
~~The Company’s~~On April 21, 2023, Amro Albanna, the Chief Executive Officer ~~(“CEO”) has provided certain periods~~ of ~~service without payment. As of June 30, 2020 and December 31, 2019, the CEO is owed $375,500 and $309,500, respectively, related to compensation. Subsequent to the period,~~ the Company, ~~issued 38,055 Units consisting of 1 share of common stock~~ and ~~1 Series A warrant and 1 Series B warrant to settle $342,500 in accrued compensation.~~
~~The Company’s~~Shahrokh Shabahang, the Chief Innovation Officer ~~(“CIO”~~of the Company, loaned $87,523 and $100,000, respectively, to the Company. The loans were each evidenced by an unsecured promissory note (the “April Note”). Pursuant to the terms each April Note, it will accrue interest at the Prime rate of eight percent (8.00%) ~~has provided certain periods~~per annum and is due on the earlier of ~~service without payment.~~October 21, 2023, or an event of default, as defined therein. As of ~~June~~September 30, ~~2020 and December 31, 2019,~~2023, the CIO is owed $476,000 and $377,000, respectively, related to compensation. Subsequent to the period, the Company issued 47,222 Units consisting of 1 share of common stock and 1 Series A warrant and 1 Series B warrant to settle $425,000 in accrued compensation.
~~Effective July 10, 2020, the Board of Directors appointed the Company’s Chief Operations Officer (“COO”). Prior to the appointment, the COO~~note was an independent operations consultant and had provided certain periods of service without payment. As of June 30, 2020 and December 31, 2019, the COO is owed $365,000 and $275,000, respectively, related to compensation. Subsequent to the period, the Company issued 35,555 Units consisting of 1 share of common stock, 1 Series A warrant, and 1 Series B warrant to settle $320,000 in accrued compensation.fully paid off.
~~-8-~~

On ~~March~~May 25, 2023, Amro Albanna, the Chief Executive Officer of the Company, loaned $200,000 to the Company. The loan was evidenced by an unsecured promissory note (the “May Note”). Pursuant to the terms of the May Note, it will accrue interest at a rate of eight and one-quarter percent (8.25%) per annum, the Prime rate on the date of signing, and is due on the earlier of November 25, 2023 or an event of default, as defined therein. As of September 30, 2023, the note was fully paid off.
On June 12, 2023, Amro Albanna, the Chief Executive Officer of the Company, and Shahrokh Shabahang, the Chief Innovation Officer of the Company, loaned $200,000 and $100,000, respectively, to the Company. The loans were evidenced by an unsecured promissory note (the “June Note”). Pursuant to the terms of the June Note, it will accrue interest at the Prime rate of eight and one-quarter percent (8.25%) per annum and is due on the earlier of December 12, 2023, or an event of default, as defined therein. As of September 30, 2023, the June Note was fully paid off.
NOTE 7 – NOTES PAYABLE
On February 21, ~~2019,~~2023, the Company entered into an agreement for the purchase and sale of future receipts (the “Future Receipts Agreement”) with a commercial funding source pursuant to which the Company agreed to sell to the funder certain future trade receipts in the aggregate amount of $2,160,000 (the “Future Receipts Purchased Amount” for gross proceeds to the Company of $1,500,000, less origination fees of $75,000. Pursuant to the Future Receipts Agreement, the Company granted the funder a security interest in all of the Company’s present and future accounts receivable in an amount not to exceed the Future Receipts Purchased Amount. The Future Receipts Purchased Amount shall be repaid by the Company in 28 weekly installments of approximately $77,000 with the final payment due on September 5, 2023. On May 30, 2023, the Company entered into the May Loan (as defined below) for gross proceeds to the Company of $2,000,000, less origination fees of $100,000 and less the full outstanding balance under the Future Receipts Agreement of $1,157,143, resulting in net proceeds to the Company of $742,857.
On April 4, 2023, the Company entered into a ~~note~~Business Loan and Security Agreement (the “April Loan Agreement”) with a ~~related party.~~commercial funding source (the “April Lender”), pursuant to which the Company obtained a loan from the April Lender in the principal amount of $1,060,000, which includes origination fees of $60,000 (the “April Loan”). Pursuant to the April Loan Agreement, the Company granted the April Lender a continuing secondary security interest in; (i) any and all amounts owed to the Company now or in the future from any merchant processor processing charges made by customers of the Company via credit card or debit card transactions, and (ii) all other tangible and intangible property. The ~~note had~~total amount of interest and fees payable by the Company to the April Lender under the April Loan (the “April Repayment Amount”) will be (i) $1,000,000 if paid prior to April 6, 2023, (ii) $1,219,000 if paid prior to April 10, 2023, or (iii) $1,590,000 if paid after April 10, 2023, and will be repaid in 20 weekly installments of $79,500 commencing on April 10, 2023 and ending on August 21, 2023. On April 24, 2023, the Company entered into the Loan Agreement (as defined below) for gross proceeds of $1,000,000, less the full outstanding balance under the April Loan Agreement of $139,500, resulting net proceeds to the Company of $860,500.
14
On April 24, 2023, the Company entered into a Business Loan and Security Agreement (the “Loan Agreement”) with a commercial funding source (the “Lender”), pursuant to which the Company obtained a loan from the Lender in the principal amount of ~~$10,000,~~$1,060,000, which includes origination fees of $60,000 (the “Loan”). Pursuant to the Loan Agreement, the Company granted the Lender a ~~maturity date~~continuing secondary security interest in; (i) any and all amounts owed to the Company now or in the future from any merchant processor processing charges made by customers of the Company via credit card or debit card transactions, and (ii) all other tangible and intangible property. The total amount of interest and fees payable by the Company to the Lender under the Loan (the “April Repayment Amount”) will be $1,590,000 and will be repaid in 20 weekly installments of $79,500. On August 23, 2023, the April Repayment Amount was restructured in connection with the August Loan Agreement, as defined below.
On May 30, 2023, the Company entered into a Business Loan and Security Agreement (the “May Loan Agreement”) with a commercial funding source (the “May Lender”), pursuant to which the Company obtained a loan from the Lender in the principal amount of $2,000,000, which includes origination fees of $100,000 (the “May Loan”). Pursuant to the May Loan Agreement, the Company granted the May Lender a continuing secondary security interest in; (i) any and all amounts owed to the Company now or in the future from any merchant processor processing charges made by customers of the Company via credit card or debit card transactions, and (ii) all other tangible and intangible property. The total amount of interest and fees payable by the Company to the Lender under the Loan will be $2,880,000 and will be repaid in 28 weekly installments of $102,857. As of September ~~21, 2019,~~30, 2023, there was a remaining principal balance of $1,041,722 on the May Loan and an unamortized debt discount of $39,286. Subsequent to the quarter, the May Loan was paid off using the proceeds from another loan. (See Note 12)
On July 3, 2023, the Company entered into a Business Loan and Security Agreement (the “July Loan Agreement”) with a commercial funding source (the “July Lender’’), pursuant to which the Company obtained a loan from the Lender in the principal amount of $215,000, which includes origination fees of $10,750 (the “July Loan”). Pursuant to the July Loan Agreement, the Company granted the July Lender a continuing secondary security interest ~~rate~~in certain collateral (as defined in the July Loan Agreement). The total amount of ~~4% per year. The note remained outstanding on June~~interest and fees payable by the Company to the Lender under the Loan (the “July Repayment Amount”) will be (i) $322,285 and will be repaid in 13 weekly installments of $24,500 with a final payment of $3,785 in the fourteenth week. As of September 30, ~~2020. This~~2023, the note was fully paid off. On August 23, 2023, the July Repayment Amount was restructured in ~~full subsequent to June 30, 2020.~~connection with the August Loan Agreement, as defined below.
~~During the six months ended June 30, 2020,~~On August 23, 2023, the Company ~~assumed $11,980~~entered into a Business Loan and Security Agreement (the “August Loan Agreement”) with a commercial funding source (the “August Lender’’), pursuant to which the Company obtained a loan from the Lender in the principal amount of ~~liabilities~~$1,400,000, which includes origination fees of $70,000 (the “August Loan”). Pursuant to the August Loan Agreement, the Company granted the August Lender a continuing secondary security interest in certain collateral (as defined in the August Loan Agreement). The total amount of interest and fees payable by the Company to the Lender under the Loan (the “Repayment Amount”) will be (i) $2,079,000 and will be repaid in 21 weekly installments of $99,000. As of September 30, 2023, there was a remaining principal balance of $1,160,962 on the August Loan and an unamortized debt discount of $53,333. Subsequent to the quarter, the August Loan was paid off using the proceeds from another loan. (See Note 12)
Securities Purchase Agreement
On July 3, 2023, the Company entered into a ~~related party~~Securities Purchase Agreement (the “First Tranche Securities Purchase Agreement”) with an accredited investor pursuant to which the Company issued and sold a secured promissory note in ~~exchange for~~ the ~~return~~principal amount of ~~5,990~~$375,000 (the “First Tranche Note”) resulting in gross proceeds to the Company of $250,000. In connection with the issuance of the First Tranche Note, the Company issued 3,907 shares of its common stock (the “First Tranche Commitment Shares”) as a commitment fee to the investor. Pursuant to the First Tranche Securities Purchase Agreement, the Company was obligated to and obtained approval of its shareholders (“First Tranche Shareholder Approval”) with respect to the issuance of any securities in connection with the First Tranche Securities Purchase Agreement and the First Tranche Note in excess of 19.99% of the Company’s issued and outstanding shares on the closing date, which was equal to 33,792 shares of the Company’s common stock. The company recognized a total debt discount of $164,775 on the Note from the issuance of stock and original issuance discount. The First Tranche Note has a maturity date of December 31, 2023, and is convertible following First Tranche Shareholder Approval and the occurrence of an Event of Default (as defined in the July Note) at a conversion price of $18.00 per share.
15

~~NOTE 5 – STOCKHOLDERS’ DEFICIT~~
~~Preferred Stock~~
~~The Company is authorized to issue 3,000,000 shares~~In connection with the First Tranche Securities Purchase Agreement and the issuance of ~~preferred stock, par value $0.001 per share.~~
~~Common Stock~~
~~The Company is authorized to issue 27,000,000 shares of common stock, par value $0.001 per share.~~
~~During~~ the ~~six months ended June 30, 2020,~~First Tranche Note, the Company ~~issued 122,250 shares~~and certain of ~~common stock~~its subsidiaries also entered into a Security Agreement with the investor (the “First Tranche Security Agreement”) pursuant to which it granted the investor a security interest in certain Collateral (as defined in the First Tranche Security Agreement) to secure its obligations under the First Tranche Note. In addition, the Company entered into a registration rights agreement with the investor pursuant to which the Company agreed to prepare and ~~recognized expense of $502,192 in stock compensation for consulting services. The Company also issued 30,975 shares of commons stock for~~file with the ~~exercise of warrants~~U.S. Securities and ~~received $185,850 for~~Exchange Commission a registration statement covering the ~~exercise~~resale of the ~~warrants. The compensation was valued based on prior private placements or based on management’s estimates of value immediately prior to the IPO.~~
~~During six months ended June 30, 2019, the Company issued 20,500 shares of common stock for services~~First Tranche Commitment Shares and ~~recognized expense of $82,000 in stock compensation, issued 71,500 shares of common stock for $235,464 in cash, net of offering costs, and received 45,356~~any shares of the Company’s common stock ~~in exchange for~~issuable upon conversion of the ~~assumption~~First Tranche Note within 120 days of ~~$90,712 in liabilities. Shares issued for compensation were valued based on~~ the ~~price which common shares were being sold in~~closing date and to have such registration statement declared effective within 150 days of the ~~above private placements.~~closing date. As of September 30, 2023, the First Tranche Note was fully paid off.
~~Reverse Stock Split~~
On June 29, 2020, the Company effectuated a 1-for-2 reverse stock split of its issued and outstanding shares of common stock by filing a certificate of amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of Delaware. Accordingly, all share and per share amounts for all periods presented in the accompanying financial statements and notes thereto have been adjusted retroactively, where applicable, to reflect this reverse stock split.
~~Stock-Based Compensation~~
In October 2017, our Board of Directors adopted the Aditx Therapeutics, Inc. 2017 Equity Incentive Plan (the “2017 Plan”). The 2017 Plan provides for the grant of equity awards to employees, and consultants. Up to 2,500,000 shares of our common stock may be issued pursuant to awards granted under the 2017 Plan. The 2017 Plan is administered by our Board of Directors, and expires ten years after adoption, unless terminated earlier by the Board.
During the six months ended June 30, 2020, the Company granted 7,500 stock options to a related party with exercise prices of $11.00 per share vesting on issuance. The total grant date fair value was determined to be $27,799.
During the six months ended June 30, 2019, the Company granted 550,000 stock options with exercise prices of $4.00 per share vesting on issuance. The total grant date fair value was determined to be $1,960,831. For all periods presented, the fair value of each stock option granted was estimated using the Black-Scholes assumption ranges and or factors as follows:
~~Exercise price~~ ~~$ 4.00-11.00~~
~~Expected dividend yield~~ 0 %
~~Risk free interest rate~~ ~~0.39% - 2.65~~ %
~~Expected life in years~~ ~~2.79-7.52~~
~~Expected volatility~~   ~~141-146~~ %
~~-9-~~
~~The risk-free interest rate assumption for options granted is based upon observed interest rates on the United States government securities appropriate for the expected term of stock options.~~
The expected term of stock options is calculated using either the simplified method for employee options which takes into consideration the contractual life and vesting terms of the options, unless the options are expected to vest in which case the contractual term of the options.
The Company determined the expected volatility assumption for options granted using the historical volatility of comparable public companies’ common stock. The Company will continue to monitor peer companies and other relevant factors used to measure expected volatility for future stock option grants, until such time that the Company’s common stock has enough market history to use historical volatility.
The dividend yield assumption for options granted is based on the Company’s history and expectation of dividend payouts. The Company has never declared or paid any cash dividends on its common stock, and the Company does not anticipate paying any cash dividends in the foreseeable future.
~~Management estimated the fair value of common stock by looking at a market approach which takes into consideration past sales of stock to third parties and Company developments to date.~~
~~The Company recognizes stock option forfeitures as they occur as there is insufficient historical data to accurately determine future forfeitures rates.~~
~~The following is an analysis of the stock option grant activity under the Plan:~~
Weighted
Average Weighted
Average
Number Exercise
Price Remaining
Life
Stock Options
Outstanding December 31, 2019 1,102,500 $ 4.00 7.77
Granted 7,500 11.00 7.52
Expired or forfeited - - -
Outstanding June 30, 2020 (unaudited) 1,110,000 $ 4.05 7.25
Nonvested Options Shares Weighted-
Average
Exercise
Price
Nonvested at December 31, 2019 - $ -
Granted 7,500 11.00
Vested (7,500 ) 11.00
Forfeited - -
Nonvested at June 30, 2020 (unaudited) - $ -
~~-10-~~
The Company recognized compensation expense related to options issued and vesting of $27,799 during the six months ended June 30, 2020, which is included in general and administrative expenses in the accompanying statements of operations. There is no additional expense to be recognized on previously granted options as of June 30, 2020. The Company recognized compensation expense related to options issued and vesting of $2,513,826 during the period ended June 30, 2019, which is included in general and administrative expenses in the accompanying statements of operations.
~~Warrants~~
~~A summary of warrant issuances are as follows:~~
Number Weighted
Average
Exercise
Price Weighted
Average
Remaining
Life
Warrants
Outstanding December 31, 2019 1,382,478 4.44 2.84
Granted 5,000 11.00 3.00
Forfeited (65,000 ) 4.00 -
Exercised (30,975 ) 6.00 -
Outstanding June 30, 2020 (unaudited) 1,291,503 $ 4.46 2.32
Nonvested Warrants Shares Weighted-
Average
Exercise
Price
Nonvested at December 31, 2019 200,000 4.00
Granted 5,000 -
Vested - -
Forfeited (65,000 ) -
Nonvested at June 30, 2020 (unaudited) 140,000 $ 4.00
~~The warrants are valued using similar inputs as noted in the stock options section above, with the exception of the expected life which is the contractual life.~~
The Company recognized compensation expense related to warrants issued and vesting of $159,777 and $226,541 during the six months ended June 30, 2020 and 2019, which is included in general and administrative in the accompanying Statements of Operations. The remaining value to be expensed is $212,093 with a weighted average vesting term of 0.97 years as of June 30, 2020.
~~During the six months ended June 30, 2020, 30,975 warrants were exercised for 30,975 shares of common stock. The Company recognized proceeds of $185,850 related to the exercises.~~
~~-11-~~
~~During the three months ended June 30, 2020, the Company issued 5,000 warrants with an exercise price of $11.00 and a term of 3 years.~~
On April 10, 2020, the Company terminated a consulting agreement dated December 1, 2018. As part of this termination agreement the consultant forfeited 65,000 non-vested. The consultant holds 25,000 warrants which were previously vested.
~~NOTE 6 – AGREEMENTS~~
~~On December 27, 2019,~~July 24, 2023, the Company entered into a ~~consulting agreement for advisory services that requires a monthly retainer payment of $2,000. The~~Securities Purchase Agreement (the “Second Tranche Securities Purchase Agreement”) with an accredited investor pursuant to which the Company issued ~~10,000~~and sold a secured promissory note in the principal amount of $2,625,000 (the “Second Tranche Note”) resulting in gross proceeds to the Company of $1,750,000. In connection with the issuance of the Second Tranche Note, the Company agreed to issue a total of 27,344 shares of its common stock ~~during January 2020. Additionally,~~(the “Second Tranche Commitment Shares”) as a commitment fee to the investor. At the request of the investor, the Company issued ~~15,000 shares~~17,278 Second Tranche Commitment Shares and will issue the remaining 10,066 Second Tranche Commitment Shares within 120 days, subject to the investor’s discretion. Pursuant to the Second Tranche Securities Purchase Agreement, the Company was obligated to and obtained approval of its ~~common stock within ten business days~~shareholders (“Second Tranche Shareholder Approval”) with respect to the issuance of any securities in connection with the Second Tranche Securities Purchase Agreement and the Second Tranche Note in excess of 19.99% of the Company’s ~~IPO~~issued and ~~will issue 15,000~~outstanding shares ~~of its common stock within ten business days of December 31, 2020.~~
~~On December 27, 2019,~~on the Company entered into a consulting agreement for advisory services. As part of this agreement the Company paid a one-time retainer of $15,000. Additionally, the Company paid a $7,500 success fee and issued 5,000 shares of its common stock within ten business days of the Company’s IPO.
On January 9, 2020, the Company entered into a consulting agreement for advisory services that requires a monthly retainer payment of $4,000. In addition, the Company issued 10,000 shares of its common stock during January 2020. Additionally, the Company issued 15,000 shares of its commons stock in June 2020 and will be required to issue 15,000 shares of its common stock within ten business days after December 17, 2020.
~~On January 10, 2020, the Company entered into a consulting agreement for advisory services,~~closing date, which was amended in May 2020. As part of this agreement the Company issued 55,000 shares of its common stock during January 2020. Additionally, the Company issued 55,000 shares of its common stock within ten business days of the Company’s IPO.
On January 22, 2020, as amended, effective July 1, 2020, the Company entered into a consulting agreement for investor relations and capital market advisory services. As part of this agreement the Company will pay a fee of $12,000 per month and issue 30,000equal to 38,026 shares of the Company’s common stock. The company recognized a total debt discount of $1.1 million on the Second Tranche Note from the issuance of stock and original issuance discount. The Note has a maturity date of December 31, 2023 and is convertible following Second Tranche Shareholder Approval and the occurrence of an Event of Default (as defined in the Second Tranche Note) at a conversion price of $15.60 per share.
~~On February 3, 2020,~~In connection with the Second Tranche Securities Purchase Agreement and the issuance of the Second Tranche Note, the Company and certain of its subsidiaries also entered into a Security Agreement with the investor (the “Second Tranche Security Agreement”) pursuant to which it granted the investor a security interest in certain Collateral (as defined in the Second Tranche Security Agreement) to secure its obligations under the Second Tranche Note. In addition, the Company entered into a ~~patent licensing agreement.~~registration rights agreement with the investor pursuant to which the Company agreed to prepare and file with the U.S. Securities and Exchange Commission a registration statement covering the resale of the Second Tranche Commitment Shares and any shares of the Company’s common stock issuable upon conversion of the Second Tranche Note within 90 days of the closing date and to have such registration statement declared effective within 120 days of the closing date. As ~~part~~ of September 30, 2023, there was $2,625,000 in outstanding principal on the Second Tranche Note, unamortized debt discount of $640,395, and accrued interest of $88,027.
NOTE 8 – LEASES
Our lease agreements generally do not provide an implicit borrowing rate; therefore, an internal incremental borrowing rate is determined based on information available at lease commencement date for purposes of determining the present value of lease payments. We used the incremental borrowing rate on September 30, 2023 and December 31, 2022 for all leases that commenced prior to that date. In determining this ~~agreement~~rate, which is used to determine the present value of future lease payments, we estimate the rate of interest we would pay on a collateralized basis, with similar payment terms as the lease and in a similar economic environment.
Our corporate headquarters is located in Richmond, Virginia, where we lease approximately 25,000 square feet. The lease expires in August 2026, subject to extension.
We also lease approximately 5,810 square feet of laboratory and office space in Mountain View, California. The lease expires in August 2024, subject to extension.
Additionally, we lease approximately 3,150 square feet of office space in Melville, New York. The lease expires in December 2024, subject to extension.
As of September 30, 2023, the Company is in arrears on certain lease payments in the aggregate amount of approximately $300,000.
16
Lease Costs
Nine Months
Ended
September 30,
2023 Nine Months
Ended
September 30,
2022
Components of total lease costs:
Operating lease expense $ 963,213 $ 988,381
Total lease costs $ 963,213 $ 988,381
Lease Positions as of September 30, 2023 and December 31, 2022
ROU lease assets and lease liabilities for our operating leases are recorded on the balance sheet as follows:
September 30,
2023 December 31,
2022
Assets
Right of use asset – long term $ 2,454,886 $ 3,160,457
Total right of use asset $ 2,454,886 $ 3,160,457

Liabilities
Operating lease liabilities – short term $ 1,081,377 $ 1,086,658
Operating lease liabilities – long term 1,203,876 1,885,218
Total lease liability $ 2,285,253 $ 2,971,876
Lease Terms and Discount Rate as of September 30, 2023
Weighted average remaining lease term (in years) – operating leases 2.29
Weighted average discount rate – operating leases 8.00 %
Maturities of leases are as follows:
Nine Months Ended September 30, 2023
2023 (remaining) $ 285,991
2024 1,004,982
2025 710,546
2026 423,930
Total lease payments $ 2,425,449
Less imputed interest (140,194 )
Less current portion (1,081,377 )
Total maturities, due beyond one year $ 1,203,876
NOTE 9 – COMMITMENTS & CONTINGENCIES
License Agreement with Loma Linda University
On March 8, 2018, we entered into an Assignment Agreement (the “Assignment Agreement”) with Sekris Biomedical, Inc. (“Sekris”). Sekris was a party to a License Agreement with Loma Linda University (“LLU”), entered into and made effective on May 25, 2011, and amended on June 24, 2011, July 16, 2012, and December 27, 2012 (the “Original Agreement,” and together with the Assignment Agreement, the “Sekris Agreements”). Pursuant to the Assignment Agreement, Sekris transferred and assigned all of its rights and obligations in and to liabilities under the Original Agreement, of whatever kind or nature, to us. In exchange, on March 8, 2018, we issued a warrant to Sekris to purchase up to 10,000 shares of our common stock (the “Sekris Warrant”). The warrant was immediately exercisable and had an exercise price of $200.00 per share. The expiration date of the warrant was March 8, 2023. On March 15, 2018, as amended on July 1, 2020, we entered into a license agreement directly with Loma Linda University (the “LLU License Agreement”), which amends and restates the Sekris Agreements.
17
Pursuant to the LLU License Agreement, we obtained the exclusive royalty-bearing worldwide license in and to all intellectual property, including patents, technical information, trade secrets, proprietary rights, technology, know-how, data, formulas, drawings, and specifications, owned or controlled by LLU and/or any of its affiliates (the “LLU Patent and Technology Rights”) and related to therapy for immune-mediated inflammatory diseases (the ADI™ technology). In consideration for the LLU License Agreement, we issued 500 shares of common stock to LLU.
Pursuant to the LLU License Agreement, we are required to pay an annual license fee to LLU. Also, we paid LLU $455,000 in July 2020 for outstanding milestone payments and license fees. We are also required to pay to LLU milestone payments in connection with certain development milestones. Specifically, we are required to make the following milestone payments: $175,000 on March 31, 2022; $100,000 on March 31, 2024; $500,000 on March 31, 2026; and $500,000 on March 31, 2027. Additionally, as consideration for prior expenses incurred by LLU to prosecute, maintain and defend the LLU Patent and Technology Rights, we made the following payments to LLU: $70,000 due at the end of December 2018, and a final payment of $60,000 due at the end of March 2019. We are required to defend the LLU Patent and Technology Rights during the term of the LLU License Agreement. Additionally, we will owe royalty payments of (i) 1.5% of Net Product Sales and Net Service Sales on any Licensed Products (defined as any finished pharmaceutical products which utilizes the LLU Patent and Technology Rights in its development, manufacture or supply), and (ii) 0.75% of Net Product Sales and Net Service Sales for Licensed Products and Licensed Services not covered by a valid patent claim for technology rights and know-how for a three (3) year period beyond the expiration of all valid patent claims. We also are required to produce a written progress report to LLU, discussing our development and commercialization efforts, within 45 days following the end of each year. All intellectual property rights in and to LLU Patent and Technology Rights shall remain with LLU (other than improvements developed by or on our behalf).
The LLU License Agreement shall terminate on the last day that a patent granted to us by LLU is valid and enforceable or the day that the last patent application licensed to us is abandoned. The LLU License Agreement may be terminated by mutual agreement or by us upon 90 days written notice to LLU. LLU may terminate the LLU License Agreement in the event of (i) non-payments or late payments of royalty, milestone and license maintenance fees not cured within 90 days after delivery of written notice by LLU, (ii) a breach of any non-payment provision (including the provision that requires us to meet certain deadlines for milestone events (each, a “Milestone Deadline”)) not cured within 90 days after delivery of written notice by LLU and (iii) LLU delivers notice to us of three or more actual breaches of the LLU License Agreement by us in any 12-month period. Additional Milestone Deadlines include: (i) submission of an IND/clinical trial application to initiate first-in-human clinical trials on or before March 31, 2022, which was extended to March 31, 2023 due to the payment of a $100,000 extension fee paid in March 2022. The Company plans to exercise its right to request the option to extend this milestone as it continues its ongoing clinical trial programs planned by its subsidiary, Adimune, (ii) the completion of first-in-human (phase I/II) clinical trials by March 31, 2024, (iii) the completion of Phase III clinical trials by March 31, 2026 and (iv) biologic licensing approval by the FDA by March 31, 2027.
License Agreement with Leland Stanford Junior University
On February 3, 2020, we entered into an exclusive license agreement (the “February 2020 License Agreement”) with Leland Stanford Junior University (“Stanford”) with regard to a patent concerning a method for detection and measurement of specific cellular responses. Pursuant to the February 2020 License Agreement, other than as described below, we received an exclusive worldwide license to Stanford’s patent with regard to use, import, offer, and sale of Licensed Products (as defined in the agreement). The license to the patented technology is exclusive, including the right to sublicense, beginning on the effective date of the agreement and ending when the patent expires. Under the exclusivity agreement, we acknowledged that Stanford had already granted a non-exclusive license in the Nonexclusive Field of Use, under the Licensed Patents in the Licensed Field of Use in the Licensed Territory (as those terms are defined in the February 2020 License Agreement”). However, Stanford agreed to not grant further licenses under the Licensed Patents in the Licensed Field of Use in the Licensed Territory. On December 29, 2021, we entered into an amendment to the February 2020 License Agreement which extended our exclusive right to license the technology deployed in AditxtScore^TMand securing worldwide exclusivity in all fields of use of the licensed technology.
18
We were obligated to pay and paid a fee of ~~$25,000. The Company~~$25,000 to Stanford within 60 days of February 3, 2020. We also issued ~~18,750~~375 shares of the Company’s common stock to ~~the patent holder. The Company is required to pay an~~Stanford. An annual licensing maintenance fee is payable by us on the first anniversary of the ~~agreement~~February 2020 License Agreement in the amount of $40,000 for 2021 through 2024 and $60,000 in starting in 2025 until the license ~~expires.~~expires upon the expiration of the patent. The Company is required to pay and has paid $25,000 for the issuances of certain patents. The Company will ~~also~~ pay milestone fees of $50,000 on the first commercial sales of a licensed product and $25,000 at the beginning of any clinical study for regulatory clearance of an in vitro diagnostic product developed and a potential licensed product. ~~The Company~~
We were also required to: (i) provide a listing of the management team or a schedule for the recruitment of key management positions by March 31, 2020 (which has been completed), (ii) provide a business plan covering projected product development, markets and sales forecasts, manufacturing and operations, and financial forecasts until at least $10,000,000 in revenue by June 30, 2020 (which has been completed), (iii) conduct validation studies by September 30, 2020 (which has been completed), (iv) hold a pre-submission meeting with the FDA by September 30, 2020 (which has been completed), (v) submit a 510(k) application to the FDA, Emergency Use Authorization (“EUA”), or a Laboratory Developed Test (“LDT”) by March 31, 2021, (which has been completed), (vi) develop a prototype assay for human profiling by December 31, 2021 (which has been completed), (vii) execute at least one partnership for use of the technology for transplant, autoimmunity, or infectious disease purposes by March 31, 2022 (which has been completed), and (viii) will ~~be responsible~~provide further development and commercialization milestones for ~~paying royalty~~specific fields of use in writing by December 31, 2022 (which has been completed).
In addition to the annual license maintenance fees outlined above, we are obligated pay Stanford royalties on Net Sales (as such term is defined in the ~~Company’s net sales. These royalty fees are set at a rate~~February 2020 License Agreement) during the of the term of the agreement as follows: 4% when ~~net sales~~Net Sales are below or equal to $5 million annually or 6% when ~~net sales~~Net Sales are above $5 million annually. The February 2020 License Agreement may be terminated upon our election on at least 30 days advance notice to Stanford, or by Stanford if we: (i) are delinquent on any report or payment; (ii) are not diligently developing and commercializing Licensed Product; (iii) miss certain performance milestones; (iv) are in breach of any provision of the February 2020 License Agreement; or (v) provide any false report to Stanford. Should any events in the preceding sentence occur, we have a thirty (30) day cure period to remedy such violation.
Asset Purchase Agreement
On April 18, 2023, the Company entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”) with Cellvera Global Holdings LLC (“Cellvera Global”), Cellvera Holdings Ltd. (“BVI Holdco”), Cellvera, Ltd. (“Cellvera Ltd.”), Cellvera Development LLC (“Cellvera Development” and together with Cellvera Global, BVI Holdco, Cellvera Ltd. and Cellvera Development (the “Sellers”), AiPharma Group Ltd. (“Seller Owner” and collectively with the Sellers, “Cellvera”), and the legal representative of Cellvera, pursuant to which, the Company will purchase Cellvera’s 50% ownership interest in G Response Aid FZE (“GRA”), certain other intellectual property and all goodwill related thereto (the “Acquired Assets”). Unless expressly stated otherwise herein, capitalized terms used but not defined herein have the meanings ascribed to them in the Asset Purchase Agreement. Pursuant to the Asset Purchase Agreement, the consideration for the Acquired Assets consists of (A) $24.5 million, comprised of: (i) the forgiveness of the Company’s $14.5 million loan to Cellvera Global, and (ii) approximately $10 million in cash, and (B) future revenue sharing payments for a term of seven years. GRA holds an exclusive, worldwide license for the antiviral medication, Avigan® 200mg, excluding Japan, China and Russia. The other 50% interest in GRA is held by Agility, Inc. (“Agility”). Additionally, upon the closing, the Share Exchange Agreement previously entered into as of December 28, 2021, between Cellvera Global Holdings, LLC f/k/a AiPharma Global Holdings, LLC (together with other affiliates and subsidiaries) and the Company, and all other related agreements will be terminated.
The obligations of the Company to consummate the closing are subject to the satisfaction or waiver, at or prior to the Closing of certain conditions, including but not limited to, the following:
(i) Satisfactory completion of due diligence;
(ii) Completion by the Company of financing sufficient to consummate the transactions contemplated by the Asset Purchase Agreement;
(iii) Receipt by the Company of all required Consents from Governmental Bodies for the Acquisition, including but not limited to, any consents required to complete the transfer and assignment of Cellvera’s membership interests in GRA;
19
(iv) Receipt of executed payoff letters reflecting the amount required to be fully pay all of each of Seller’s and Seller Owner’s Debt to be paid at Closing;
(v) Receipt by the Company of a release from Agility;
(iv) Execution of an agreement acceptable to the Company with respect to the acquisition by the Company of certain intellectual property presently held by a third party;
(v) Execution of an amendment to an asset purchase agreement previously entered into by Cellvera with a third party that effectively grants the Company the rights to acquire the intellectual property from the third party under such agreement;
(vi) Receipt of a fairness opinion by the Company with respect to the transactions contemplated by the Asset Purchase Agreement; and
(vii) Receipt by the Company from the Seller Owner of written consent, whether through its official liquidator or the Board of Directors of Seller Owner, to the sale and purchase of the Acquired Assets and Assumed Liabilities pursuant to the Assert Purchase Agreement.
Off Balance Sheet Arrangements
From time to time the Company enters into short term research and development contracts. These contracts have payment provisions which require payment once regulatory and completion milestones are met. As of September 30, 2023, the Company has approximately $1.8 million outstanding, subject to these milestones.
Departure of Officer
On ~~February 23, 2020,~~July 21, 2023, Matthew Shatzkes tendered his resignation as Chief Legal Officer, General Counsel and Corporate Secretary of the Company. In connection with his resignation, the Company entered into a ~~consulting agreement for business development services. As part of this agreement~~Separation Agreement and General Release (the “Separation Agreement”) with Mr. Shatzkes. Pursuant to the Separation Agreement, Mr. Shatzkes’ employment with the Company issued 5,000 shares of its common stock. The Company also issued an additional 3,000 shares of its common stock upon the completion of its IPO. Subsequent to the IPO the Company will pay a monthly fee of $8,000. The Company will also pay a success fee equal to 4% of transaction proceeds in connection with qualified transactions.
On March 30, 2020, the Company entered into an employment agreement for a permanent, full-time Chief Financial Officer that is effective upon the closing of the Company’s IPO. As part of the employment agreementterminated on August 4, 2023 (the “Termination Date”). In addition, the Company agreed to pay Mr. Shatzkes’ within seven days after the ~~employee $225,000 per year.~~Termination Date: (i) $122,292, representing all accrued salary and wages (inclusive of Base Compensation and earned Subsequent Quarterly Bonus amounts, as those terms are defined in Mr. Shatzkes’ employment agreement), and (ii) $32,576, representing Mr. Shatzkes accrued, but unused paid time off (collectively, the “Initial Payment”). The Company also agreed to pay Mr. Shatzkes: (i) $385,000, representing 12 months of Mr. Shatzkes’ Base Compensation (as that term is defined in Mr. Shatzkes employment agreement), and (ii) $290,000, representing Mr. Shatzkes Subsequent Year Minimum Bonus (as such term is defined in Mr. Shatzkes employment agreement), on the 60^th day following the Termination Date. In addition, the Company shall reimburse Mr. Shatzkes COBRA premium for a period of 12 months and shall cause any restricted stock units granted to Mr. Shatzkes to immediately vest as of the Termination Date. As of September 30, 2023, the Company has completed all obligations under the Separation Agreement.
Contingent Liability
On September 7, 2023, the Company received a demand letter from the holder of certain warrants issued by the Company in April 2023. The demand letter alleges that the investor suffered more than $2 million in damages as a result of the Company failing to register the shares of common of the Company’s common stock ~~options~~underlying the warrants as required under the securities purchase agreement. The Company denies the amount of the liability claimed by the investor and intends to ~~purchase~~defend itself vigorously against any such claims. The Company is engaged in ongoing discussions with the investor and, as a result, has accrued a loss of $1.6 million relating to the potential liability.
Letter of Intent Termination
On August 1, 2023, the Company and Natural State Genomics and Natural State Laboratories mutually agreed to terminate the Amended and Restated Non-Binding Letter of Intent dated June 12, 2023.
20
NOTE 10 – STOCKHOLDERS’ EQUITY (DEFICIT)
Common Stock
On May 24, 2021, the Company increased the number of authorized shares of the Company’s common stock, par value $0.001 per share, from 27,000,000 to 100,000,000 (the “Authorized Shares Increase”) by filing a Certificate of Amendment (the “Certificate of Amendment”) to its Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware. In accordance with the General Corporation Law of the State of Delaware, the Authorized Shares Increase and the Certificate of Amendment were approved by the stockholders of the Company at the Company’s Annual Meeting of Stockholders on May 19, 2021. On September 13, 2022, the Company effectuated a 1 for 50 reverse stock split (the “2022 Reverse Split”). The Company’s stock began trading at the 2022 Reverse Split price effective on the Nasdaq Stock Market on September 14, 2022. There was no change to the number of authorized shares of the Company’s common stock. ~~An initial grant~~On August 17, 2023, the Company effectuated a 1 for 40 reverse stock split (the “2023 Reverse Split”). The Company’s stock began trading at the 2023 Reverse Split price effective on the Nasdaq Stock Market on August 17, 2023. There was no change to the number of ~~7,500 options was made upon the signing~~authorized shares of the ~~agreement~~Company’s common stock.
During the nine months ended September 30, 2023, the Company issued 4,675 shares of common stock and ~~a subsequent grant~~recognized expense of ~~165,000 options was made upon~~$168,300 in stock-based compensation for consulting services. The stock-based compensation for consulting services is calculated by the ~~completion~~number shares multiplied by the closing price on the effective date of the ~~IPO.~~contract. During the nine months ended September 30, 2023, 170 Restricted Stock Units (“RSUs”) vested which resulted in the issuance of shares. The ~~initial grant has an exercise price~~Company recognized expense of ~~$11.00 and expires on October 5, 2027,~~$308,479 in stock-based compensation related to the ~~subsequent grant was~~RSUs for the nine months ended September 30, 2023. The stock-based compensation for shares issued ator RSUs granted during the ~~IPO price. The initial grant vested immediately and the subsequent grant vests 1/3~~period were valued based on the ~~first anniversary~~fair market value on the date of grant. During the ~~agreement~~nine months ended September 30, 2023, the Company issued 184,374 shares of common stock for the exercise of prefunded warrants.
During the nine months ended September 30, 2022, the Company issued 413 shares of common stock and recognized expense of $253,719 in stock-based compensation for consulting services. The Company also granted 291 RSUs, 379 vested and resulted in the ~~remaining 2/3 vests quarterly over~~issuance of shares. As a result, the ~~next two years.~~Company recognized expense of $993,462 in stock-based compensation. The stock-based compensation for shares issued or RSU’s granted during the period were valued based on the fair market value on the date of grant.
~~-12-~~
On ~~April 30, 2020,~~December 20, 2022, the Company entered into an ~~employment agreement for a Vice President of Preclinical Research and Development that is effective upon the closing of the Company’s IPO. As part of the employment agreement,~~At The Market Offering Agreement (the “ATM”) with H.C. Wainwright & Co., LLC as agent (the “Agent”), pursuant to which the Company ~~agreed~~may offer and sell, from time to ~~pay~~time through the ~~employee $200,000 per year. The Company granted 90,000 stock options to purchase~~Agent, shares of the Company’s common stock ~~upon the completion~~having an aggregate offering price of up to $50,000,000 (the “Shares”).
The offer and sale of the ~~IPO.   The initial grant has~~Shares was made pursuant to a shelf registration statement on Form S-3 and the related prospectus (File No. 333-257645) filed by the Company with the SEC on July 2, 2021, amended on July 6, 2021 and declared effective by the SEC on July 13, 2021, under the Securities Act of 1933, as amended.
For the nine months ended September 30, 2023, the Company sold 8,466 Shares at an ~~exercise~~average price of ~~equal to that~~$62.05 per share under the ATM. The sale of ~~the IPO~~Shares generated net proceeds of $507,016 after paying commissions and expires on October 5, 2027. The grant vests 1/3 on the first anniversary of the start date of the employee and the remaining 2/3 vests quarterly over the following two years starting on the end of the 15^th ~~month following the start date.~~related fees.
On ~~May 16, 2020,~~April 20, 2023, the Company entered into an ~~employment agreement for a Vice President of Innovation Portfolio~~amendment to the ATM, pursuant to which the Company and ~~Development that is effective upon~~ the ~~closing~~Agent agreed to reduce the aggregate gross sales price of the ~~Company’s IPO. As part~~Shares under the ATM from $50,000,000 to zero.
Preferred Stock
The Company is authorized to issue 3,000,000 shares of preferred stock, par value $0.001 per share. There were no shares of preferred stock outstanding as of September 30, 2023 and December 31, 2022, respectively.
Issuance of Series B Preferred Stock:
On July 19, 2022, the ~~employment agreement,~~Company entered into a Subscription and Investment Representation Agreement with its Chief Executive Officer (the “Purchaser”), pursuant to which the Company agreed to ~~pay~~issue and sell one (1) share of the ~~employee $200,000~~Company’s Series B Preferred Stock (the “Preferred Stock”), par value $0.001 per ~~year.~~share, to the Purchaser for $20,000 in cash.
21
On July 19, 2022, the Company filed a certificate of designation (the “Certificate of Designation”) with the Secretary of State of Delaware, effective as of the time of filing, designating the rights, preferences, privileges and restrictions of the share of Preferred Stock. The ~~Company granted 90,000 stock options to purchase~~Certificate of Designation provides that the share of Preferred Stock will have 250,000,000 votes and will vote together with the outstanding shares of the Company’s common stock as a single class exclusively with respect to any proposal to amend the Company’s Restated Certificate of Incorporation to effect a reverse stock split of the Company’s common stock. The Preferred Stock will be voted, without action by the holder, on any such proposal in the same proportion as shares of common stock are voted. The Preferred Stock otherwise has no voting rights except as otherwise required by the General Corporation Law of the State of Delaware.
The Preferred Stock is not convertible into, or exchangeable for, shares of any other class or series of stock or other securities of the Company. The Preferred Stock has no rights with respect to any distribution of assets of the Company, including upon a liquidation, bankruptcy, reorganization, merger, acquisition, sale, dissolution or winding up of the Company, whether voluntarily or involuntarily. The holder of the Preferred Stock will not be entitled to receive dividends of any kind.
The outstanding share of Preferred Stock shall be redeemed in whole, but not in part, at any time (i) if such redemption is ordered by the Board of Directors in its sole discretion or (ii) automatically upon the ~~completion~~effectiveness of the ~~IPO.   The initial grant has an exercise price~~amendment to the Certificate of ~~equal to that~~Incorporation implementing a reverse stock split. Upon such redemption, the holder of the ~~IPO and expires~~Preferred Stock will receive consideration of $20,000 in cash. On September 13, 2022, the share was redeemed.
Redemption of Series B Preferred Stock
On October 7, 2022, the Company paid $20,000 in consideration for the one share of Preferred Stock which was redeemed on ~~October 5, 2027. The grant vests 1/3 on~~September 13, 2022.
Series C Preferred Stock
On July 11, 2023, the ~~first anniversary~~Company filed a certificate of designation (the “Certificate of Designation”) with the Secretary of State of Delaware, effective as of the ~~start date~~time of filing, designating the rights, preferences, privileges and restrictions of the ~~employee~~share of Preferred Stock. The Certificate of Designation provides that the share of Preferred Stock will have 250,000,000 votes and will vote together with the ~~remaining 2/3 vests quarterly over the following two years starting on the end of the 15~~^th ~~month following the start date.~~
~~On June 15, 2020 the Company entered into a consulting agreement for advisory services that required a fee equivalent to 3,000~~outstanding shares of the Company’s common stock ~~which were issued~~as a single class exclusively with respect to any proposal to amend the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company’s common stock. The Preferred Stock will be voted, without action by the holder, on any such proposal in ~~July 2020.~~the same proportion as shares of common stock are voted. The Preferred Stock otherwise has no voting rights except as otherwise required by the General Corporation Law of the State of Delaware.
~~NOTE 7 – NOTES PAYABLE~~
~~On April 12, 2018,~~The Preferred Stock is not convertible into, or exchangeable for, shares of any other class or series of stock or other securities of the Company. The Preferred Stock has no rights with respect to any distribution of assets of the Company, ~~issued an unsecured promissory note for $35,000 that accrued interest~~including upon a liquidation, bankruptcy, reorganization, merger, acquisition, sale, dissolution or winding up of ~~4% annually.~~the Company, whether voluntarily or involuntarily. The ~~note was due on~~holder of the ~~earlier~~Preferred Stock will not be entitled to receive dividends of ~~November 12, 2018~~any kind.
The outstanding share of Preferred Stock shall be redeemed in whole, but not in part, at any time (i) if such redemption is ordered by the Board of Directors in its sole discretion or (ii) automatically upon the effectiveness of the amendment to the Certificate of Incorporation implementing a reverse stock split. Upon such redemption, the holder of the Preferred Stock will receive consideration of $1,000 in cash. As of September 30, 2023, the ~~event of default, as defined in~~share has been redeemed and the ~~agreement. This note was paid in full subsequent to June 30, 2020.~~consideration has not been paid.
~~-13-~~
On July ~~10, 2018,~~11, 2023, the Company entered into a ~~bridge loan~~Subscription and Investment Representation Agreement (the “Subscription Agreement”) with Amro Albanna, its Chief Executive Officer, who is an accredited investor (the “Purchaser”), pursuant to which the Company agreed to issue and sell one (1) share of the Company’s Series C Preferred Stock, par value $0.001 per share (the “Preferred Stock”), to the Purchaser for $1,000 in cash. The sale closed on July 11, 2023. The Subscription Agreement contains customary representations and warranties and certain indemnification rights and obligations of the parties.
22
Stock-Based Compensation
In October 2017, our Board of Directors adopted the Aditx Therapeutics, Inc. 2017 Equity Incentive Plan (the “2017 Plan”). The 2017 Plan provides for the grant of equity awards to directors, employees, and consultants. The Company is authorized to issue up to 2,500,000 shares of our common stock pursuant to awards granted under the 2017 Plan. The 2017 Plan is administered by our Board of Directors, and expires ten years after adoption, unless terminated earlier by the Board of Directors. All shares of our common stock pursuant to awards under the 2017 Plan have been awarded.
On February 24, 2021, our Board of Directors adopted the Aditx Therapeutics, Inc. 2021 Omnibus Equity Incentive Plan (the “2021 Plan”). The 2021 Plan provides for grants of nonqualified stock options, incentive stock options, stock appreciation rights, restricted stock and restricted stock units, and other stock-based awards (collectively, the “Awards”). Eligible recipients of Awards include employees, directors or independent contractors of the Company or any affiliate of the Company. The Compensation Committee of the Board of Directors (the “Committee”)administers the 2021 Plan. A total of 60,000 shares of common stock, par value $0.001 per share, of the Company may be issued pursuant to Awards granted under the 2021 Plan. The exercise price per share for the shares to be issued pursuant to an exercise of a ~~principal~~stock option will be no less than one hundred percent (100%) of ~~$15,600. The note was due on~~ the ~~earlier of October 8, 2018 or in the event of default, as~~Fair Market Value (as defined in the ~~agreement. This note~~2021 Plan) of a share of Common Stock on the date of grant. The 2021 Plan was ~~paid~~submitted and approved by the Company’s stockholders at the 2021 annual meeting of stockholders, held on May 19, 2021.
During the three and nine months ended September 30, 2023 and 2022, the Company granted no new options.
The following is an analysis of the stock option grant activity under the Plan:
Vested and Nonvested Stock Options Number Weighted
Average
Exercise
Price Weighted
Average
Remaining
Life
Outstanding December 31, 2022 1,127 $ 6,802.93 5.74
Granted - - -
Exercised - - -
Expired or forfeited - - -
Outstanding September 30, 2023 1,127 $ 6,802.93 5.00
Nonvested Stock Options Number Weighted-
Average
Exercise
Price
Nonvested on December 31, 2022 55 $ 3,840
Granted - -
Vested (55 ) 3,840
Forfeited - -
Nonvested on September 30, 2023 - $ -
As of September 30, 2023 there were 1,127 exercisable options; these options had a weighted average exercise price $6,802.93.
The Company recognized stock-based compensation expense related to options granted and vesting expense of $59,964 during the three months ended September 30, 2023, of which $24,429 is included in ~~full subsequent~~general and administrative expenses and $35,535 is included in research and development expenses in the accompanying statements of operations. The remaining value to ~~June~~be expensed is zero as of September 30, ~~2020.~~ 2023. The weighted average vesting term is zero years as of September 30, 2023. The Company recognized stock-based compensation expense related to options granted and vesting expense of $660,191 during the nine months ended September 30, 2022, of which $472,156 is included in general and administrative expenses and $188,035 is included in research and development expenses in the accompanying statements of operations.
The Company recognizes option forfeitures as they occur, as there is insufficient historical data to accurately determine future forfeitures rates.
23
Warrants
For the nine months ended September 30, 2023, the fair value of each warrant granted was estimated using the assumption and/or factors in the Black-Scholes Model as follows:

Exercise price $ 10.00-12.50
Expected dividend yield 0 %
Risk free interest rate 4.44 %
Expected life in years 5.50
Expected volatility 171 %
The risk-free interest rate assumption for warrants granted is based upon observed interest rates on the United States Government Bond Equivalent Yield appropriate for the expected term of warrants.
The Company determined the expected volatility assumption for warrants granted using the historical volatility of comparable public companies’ common stock. The Company will continue to monitor peer companies and other relevant factors used to measure expected volatility for future warrant grants, until such time that the Company’s common stock has enough market history to use historical volatility.
The dividend yield assumption for warrants granted is based on the Company’s history and expectation of dividend payouts. The Company has never declared nor paid any cash dividends on its common stock, and the Company does not anticipate paying any cash dividends in the foreseeable future.
The Company recognizes warrant forfeitures as they occur, as there is insufficient historical data to accurately determine future forfeitures rates.
A summary of warrant issuances are as follows:
Vested and Nonvested Warrants Number Weighted
Average
Exercise
Price Weighted
Average
Remaining
Life
Outstanding December 31, 2022 127,281 $ 514.97 4.54
Granted 2,190,367 6.36 5.20
Exercised (184,374 ) 1.35 -
Expired or forfeited (392 ) 8,250.00 -
Outstanding September 30, 2023 2,132,882 $ 35.22 5.10
On September 1, 2023, the Company recognized a deemed dividend resulting in the issuance of 9,086 warrants, 6,128 of which were immediately exercised.
On ~~July 18, 2018,~~August 31, 2023, the Company entered into a ~~bridge loan~~securities purchase agreement with an institutional investor for the issuance and sale in a ~~principal~~private placement of ~~$130,000.~~(i) pre-funded warrants (the “August 2023 Pre-Funded Warrants”) to purchase up to 1,000,000 shares of the Company’s common stock, at an exercise price of $0.001 per share, and (ii) warrants to purchase up to 1,000,000 shares of the Company’s Common Stock at an exercise price of $10.00 per share. In addition, the Company issued to the exclusive placement agent on this transaction, Wainwright or its designees, warrants to purchase up to an aggregate of 60,000 shares of Common Stock. The ~~note was due on~~August 2023 Pre-Funded Warrants do not have an expiration date, therefore the ~~earlier~~August 2023 Pre-Funded Warrants have been excluded from the weighted average remaining life calculation.
Nonvested Warrants Number Weighted-
Average
Exercise
Price
Nonvested on December 31, 2022 2,500 $ 300.00
Granted 2,190,367 6.36
Vested (2,192,867 ) 6.70
Forfeited - -
Nonvested on September 30, 2023 - $ -
24
The Company recognized stock-based compensation expense related to warrants granted and vesting expense of ~~October 16, 2018 or~~zero and $660,191 during the nine months ended September 30, 2023 and 2022, respectively, which is included in general and administrative in the ~~event~~accompanying Statements of ~~default,~~Operations. The remaining value to be expensed is zero as ~~defined in the agreement. This note was paid in full subsequent to June~~of September 30, ~~2020.~~ 2023. The weighted average vesting term is zero years as of September 30, 2023.
On ~~November 1, 2019,~~April 20, 2023, the Company entered into a ~~bridge loan~~securities purchase agreement (the “Purchase Agreement”) with an institutional investor, pursuant to which the Company agreed to sell to such investor pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 39,634 shares of common stock of the Company (the “Common Stock”) at a principal of $50,000. This loan did not accrue any interest. The note was due on the earlier of April 28, 2020 or in the event of default, as defined in the agreement. The note was convertible into the same class of securities as those sold in the public offering with a conversionpurchase price of ~~$2.00~~$48.76 per ~~share. On July 24, 2020,~~Pre-Funded Warrant, resulting in proceeds of approximately $1.6 million after deducting approximately $291,000 in commissions and closing fees. Concurrently with the sale of the Pre-Funded Warrants, pursuant to the Purchase Agreement in a concurrent private placement, for each Pre-Funded Warrant purchased by the investor, such investor received from the Company ~~entered into~~ an ~~exchange agreement with respect~~unregistered warrant (the “Warrant”) to purchase two shares of Common Stock. The warrants have an exercise price of $34.40 per share and are exercisable for a three year period. In addition, the Company issued a warrant to the ~~previously issued note~~placement agent to ~~exchange the note into Units on the same terms as the securities offered by the Company in its IPO. The note was converted in full subsequent~~purchase up to ~~June 30, 2020.~~2,379 shares of common stock at an exercise price of $61.00 per share.
On ~~January 10, 2020,~~August 31, 2023, the Company entered into a ~~bridge loan~~securities purchase agreement (the “August Purchase Agreement”) with an institutional investor for the issuance and sale in a ~~principal amount~~private placement (the “Private Placement”) of $75,000. This Note carried an original issue discount of $40,000. This loan did not accrue any interest. The note was due on the earlier of July 8, 2020 or in the event of default, as defined in the agreement, as amended. The note was convertible into the same class of securities as those sold in the public offering with a conversion price of $2.00 per share. The note was converted in full subsequent(i) pre-funded warrants (the “Pre-Funded Warrants”) to ~~June 30, 2020.~~
During the first quarter of 2020, the Company entered into six bridge loans with a total principal amount of $600,000. These notes carried a total original issue discount of $300,000. The notes were due on the earlier of April 19, 2020 or ten days after the closepurchase up to 1,000,000 shares of the Company’s ~~IPO.~~common stock at an exercise price of $0.001 per share, and (ii) warrants (the “Common Warrants”) to purchase up to 1,000,000 shares of the Company’s Common Stock at an exercise price of $10.00 per share. 60,000 warrants were also issued to the placement agent. These ~~notes~~warrants had an exercise price of $12.50 and a term of 5.5 years. The Common Warrants were ~~paid~~valued at $32.3 million and the 60,000 warrants issued to the placement agents were valued at $1.9 million using a Black Scholes valuation model. The Private Placement closed on September 6, 2023. The net proceeds to the Company from the Private Placement were approximately $9 million, after deducting placement agent fees and expenses and estimated offering expenses payable by the Company. The Company intends to use the net proceeds received from the Private Placement for (i) the payment of approximately $3.1 million in outstanding obligations, (ii) the repayment of approximately $0.4 million of outstanding debt, and (iii) the balance for continuing operating expenses and working capital.
Restricted Stock Units
A summary of Restricted Stock Units (“RSUs”) issuances are as follows:
Nonvested RSUs Number Weighted
Average
Price
Nonvested December 31, 2022 187 $ 1,856,21
Granted - -
Vested (170 ) 2,714.15
Forfeited (35 ) 1,345.77
Rounding for Reverse Split 18 -
Nonvested September 30, 2023 - $ -
The Company recognized stock-based compensation expense related to RSUs granted and vesting expense of $308,479 and $993,462 during the nine months ended September 30, 2023 and September 30, 2022, respectively. Of the $308,479, $242,915 is included in general and administrative, $58,777 is included in research and development, and $6,787 is included in sales and marketing in the accompanying Statements of Operations. The remaining value to be expensed is $0 with a weighted average vesting term of 0 years as of September 30, 2023.
During the nine months ended September 30, 2023, the Company granted a total of zero RSUs. During the nine months ended September 30, 2023, 170 RSUs vested and the Company issued 157 shares of common stock for the 170 vested RSUs.
25
NOTE 11 – INCOME TAXES
The Company has incurred losses since inception. During the nine months ended September 30, 2023, the Company did not provide any provision for income taxes as the Company incurred losses during such period. The Company accounts for income taxes using the asset and liability method in accordance with ASC 740, “Accounting for Income Taxes”. The asset and liability method provides that deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities and for operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using the currently enacted tax rates and laws that will be in effect when the differences are expected to reverse. In assessing the need for a valuation allowance, the Company has considered both positive and negative evidence related to the likelihood of realization of deferred tax assets using a “more likely than not” standard. In making such assessment, more weight was given to evidence that could be objectively verified, including recent cumulative losses. Based on the Company’s review of this evidence, the Company has recorded a full ~~subsequent~~valuation allowance for its net deferred tax assets as of September 30, 2023.
As of September 30, 2023, the Company did not have any amounts recorded pertaining to ~~June 30, 2020.~~uncertain tax positions.
NOTE 912 – SUBSEQUENT EVENTS
Purchase and Sale of Future Receipts
On ~~July 1, 2020,~~October 5, 2023, the Company entered into an ~~amendment~~Agreement for the Purchase and Sale of Future Receipts (the “October MCA Agreement”) pursuant to ~~patent~~which the existing funder (the “Funder”) increased the existing outstanding amount to $4,470,000 (the “October MCA Purchased Amount”) for gross proceeds to the Company of $3,000,000, less origination fees of $240,000 and ~~technology licensing~~the outstanding balance under the existing agreement ~~with Loma Linda University (“LLU”), dated March 15, 2018.~~of $1,234,461, resulting in net proceeds to the Company of $1,525,539. Pursuant to the ~~amendment,~~October MCA Agreement, the Company ~~was to pay LLU $455,000 within four days~~granted the Funder a security interest in all of the ~~signing~~Company’s present and future accounts receivable in an amount not to exceed the October MCA Purchased Amount. The October MCA Purchased Amount shall be repaid by the Company in 30 weekly installments of ~~such amendment.~~$149,000. The ~~amendment also updated~~October Purchased Amount may be prepaid by the ~~milestone~~Company via a payment ~~dates to be $175,000 on March 31, 2022; $100,000 on March 31, 2024; $500,000 on March 31, 2026;~~of $3,870,000 if repaid within 30 days, $4,110,000 if repaid within 60 days and ~~$500,000 on March 31, 2027.~~$4,230,000 if repaid within 90 days.
~~Effective on July 1, 2020,~~Business Loan and Security Agreement
On November 7, 2023, the Company entered into a ~~consulting agreement for investor relations~~Business Loan and ~~public relations services. As part of this agreement~~Security Agreement (the “November Loan Agreement”) with the lender (the “Lender”), pursuant to which the Company ~~will pay~~obtained a ~~fee~~loan from the Lender in the principal amount of ~~$8,000 per month~~$2,100,000, which satisfied the outstanding balances on the August Loan and ~~issue 20,000 shares~~includes origination fees of $140,000 (the “November Loan”). Pursuant to the ~~Company’s common stock.~~
~~On July 2, 2020,~~November Loan Agreement, the Company ~~completed its IPO. (See Note 1).~~
~~On July 2, 2020,~~granted the ~~Company settled outstanding compensation with~~Lender a continuing secondary security interest in certain ~~related parties. (See Note 4)~~collateral (as defined in the November Loan Agreement).
~~See Note 6 for descriptions~~ The total amount of ~~agreements that required shares~~interest and fees payable by us to the Lender under the November Loan will be ~~issued or options to~~$3,129,000, which will be ~~granted upon completion of the Company’s IPO. Such shares have been issued and options granted.~~
~~Subsequent to June 30, 2020, the Company~~ repaid ~~or exchanged for shares all debt agreements described~~ in ~~Note 8.~~ 34 weekly installments ranging from $69,000 - $99,000.
~~-14-~~
26

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following discussion and analysis of our financial condition and results of operations should be read together with ~~our~~the unaudited condensed consolidated financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q and ~~our~~the audited financial statements and related notes for the year ended December 31, ~~2019~~2022 included in our ~~final prospectus for our initial public offering of our common stock~~Annual Report on Form 10-K filed with the Securities and Exchange Commission, or ~~SEC, pursuant to Rule 424(b) of the Securities Act, dated June 29, 2020, which we refer to as the Prospectus of Aditx Theraputics,Inc.(the “Company,” “Aditxt”, “we,” or “our”~~SEC. In addition to historical information, this discussion and analysis contains forward-looking statements that involve risks, uncertainties, and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of certain factors. We discuss factors that we believe could cause or contribute to these differences below and elsewhere in this Quarterly Report on Form 10-Q, including those factors set forth in the section entitled “Cautionary Note Regarding Forward-Looking Statements and Industry Data” and in the section entitled “Risk Factors” in Part II, Item 1A.
Overview and Mission
We believe the world needs—and deserves—a new approach to innovating that harnesses the power of large groups of stakeholders who work together to ensure that the most promising innovations make it into the hands of people who need them most.
We were incorporated in the State of Delaware on September 28, 2017, and our headquarters are ~~a life sciences~~in Richmond, Virginia. The company was founded with a mission of bringing stakeholders together, to transform promising innovations into products and services that could address some of the most challenging needs. The socialization of innovation through engaging stakeholders in every aspect of it, is key to transforming more innovations, more rapidly, and more efficiently.
At inception, the first innovation we took on was an immune modulation technology titled ADI/Adimune with a focus on prolonging life and enhancing ~~its~~life quality ~~by improving~~of patients that have undergone organ transplants. Since then, we expanded our portfolio of innovations, and we continue to evaluate a variety of promising health innovations.
ADIMUNE, INC.
Formed in January 2023, Adimune™, Inc. (“Adimune”) is focused on leading our immune modulation therapeutic programs. Adimune’s proprietary immune modulation product candidate, ADI-100™, based on the ~~health~~Apoptotic DNA Immunotherapy™ platform technology, utilizes a novel approach that mimics the way our bodies naturally induce tolerance to our own tissues. It includes two DNA molecules designed to deliver signals to induce tolerance. ADI-100 has been successfully tested in several preclinical models (e.g., skin grafting, psoriasis, type 1 diabetes, multiple sclerosis).
In May 2023, Adimune entered into a clinical trial agreement with Mayo Clinic to advance clinical studies targeting autoimmune diseases of the ~~immune system. Our immune reprogramming technology~~central nervous system (“CNS”) with the initial focus on the rare, but debilitating, autoimmune disease Stiff Person Syndrome (“SPS”). According to the National Organization of Rare Diseases, the exact incidence and prevalence of SPS is ~~currently~~unknown; however, one estimate places the incidence at approximately one in one million individuals in the ~~pre-clinical stage~~general population.
Pending approval by the International Review Board, a human trial for SPS is expected get underway in the first half of 2024 with enrollment of up to 20 patients, some of whom may also have type 1 diabetes. ADI-100 will initially be tested for safety and ~~designed to retrain the immune system to induce tolerance with an objective of addressing rejection of transplanted organs, autoimmune diseases, and allergies. Our immune monitoring technology~~efficacy. ADI-100 is designed to ~~provide a personalized comprehensive profile~~tolerize against an antigen known as glutamic acid decarboxylase (“GAD”), which is implicated in type-1 diabetes, psoriasis, stiff person syndrome, and in many autoimmune diseases of the immune system and we plan to utilize it in our upcoming clinical trials to monitor subjects’ immune response before, during and after drug administration. We are also evaluating plans to obtain FDA approval for this monitoring tool’s use as a clinical assay.CNS.
27

~~Immune Reprogramming~~
Background
The discovery of immunosuppressive (anti-rejection and monoclonal) drugs over 40 years ago has made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. However, immune suppression leads to significant undesirable side effects, such as increased susceptibility to life-threatening infections and cancers, because it indiscriminately and broadly suppresses immune function throughout the body. While the use of these drugs has been justifiable because they prevent or delay organ rejection, their use for treatment of autoimmune diseases and allergies may not be acceptable because of the aforementioned side effects. Furthermore, often transplanted organs ~~often~~ ultimately fail despite the use of immune suppression, and about 40% of transplanted organs survive no more than 5five years.
~~New, focused therapeutic approaches are needed that modulate only~~Through Aditxt, Adimune has the ~~small portion~~right of immune cells that are involved in rejection of the transplanted organ, as this approach can be safer for patients than indiscriminate immune suppression.  Such approaches are referred to as immune tolerance, and when therapeutically induced, may be safer for patients and also potentially allow long-term survival of transplanted tissues and organs.
In the late 1990s, academic research on these approaches was conducted at the Transplant Center in Loma Linda University (“LLU”) in connection with a project that secured initial grant funding from the U.S. Department of Defense.  The focus of that project was for skin grafting for burn victims.  Twenty years of research at LLU and an affiliated incubator led to a series of discoveries that have been translated into a large patent portfolio of therapeutic approaches that may be applieduse to the ~~modulation of the immune system in order to induce tolerance to self and transplanted organs.~~
~~We have an~~ exclusive worldwide license for commercializing ~~this~~ADI nucleic acid-based technology (which is currently at the pre-clinical stage)~~, named Apoptotic DNA Immunotherapy™ (ADi™)~~ from ~~LLU, which utilizes~~Loma Linda University. ADI uses a novel approach that mimics the way the body naturally induces tolerance to our own tissues (“therapeutically induced immune tolerance”). While immune suppression requires continuous administration to prevent rejection of a transplanted organ, induction of tolerance has the potential to retrain the immune system to accept the organ for longer periods of time. ~~Thus, ADi™~~ADI may allow patients to live with transplanted organs with significantly reduced immune suppression. ~~ADi™~~ADI is a technology platform which we believe can be engineered to address a wide variety of indications.
~~-15-~~
~~We are developing ADi™ products for organ transplantation including skin grafting, autoimmune diseases, and allergies, with the initial focus on skin allografts and psoriasis, as~~Advantages
ADI™ is a nucleic acid-based technology (e.g., DNA-based), which we believe ~~these indications will be most efficient~~selectively suppresses only those immune cells involved in ~~providing safety~~attacking or rejecting self and ~~efficacy data in clinical trials. To submit a Biologics License Application (“BLA”) for a biopharmaceutical product, clinical safety~~transplanted tissues and ~~efficacy must be demonstrated in a series~~organs. It does so by tapping into the body’s natural process of ~~clinical studies conducted with human subjects. For products in our class of drugs,~~cell turnover (i.e., apoptosis) to retrain the first-in-human trials will be a combination of Phase I (safety/tolerability) and Phase II (efficacy) in affected subjects. To obtain approval to initiate the Phase I/IIa studies, an Investigational New Drug Application will be submitted to compile non-clinical efficacy data as well as manufacturing and pre-clinical safety/toxicology data. To date, we have conducted non-clinical studies in a stringent model of skin transplantation using genetically mismatched donor and recipient animals demonstrating a 3-fold increase in the survival of the skin graft in animals that were tolerized with ADi™ compared to animals that receive immune suppression alone. Prolongation of graft life was observed despite discontinuation of immune suppression after the first 5 weeks. Additionally, in an induced non-clinical model for psoriasis, ADi™ treatment resulted in a 69% reduction in skin thickness and a 38% decrease in skin flaking (two clinical parameters for assessment of psoriasis skin lesions). The Phase I/IIa studies in psoriasis will evaluate the safety/tolerability of ADi™ in patients diagnosed with psoriasis. Since the drug will be administered in subjects diagnosed with psoriasis, effectiveness of the drug to improve psoriatic lesions will also be evaluated. In another Phase I/IIa study, patients requiring skin allografts will receive weekly intra-dermal injections of ADi™ in combination with standard immune suppression to assess safety/tolerability and possibility of reducing levels of immunosuppressive drugs as well as prolongation of graft life. Later phase trials are planned after successful completion of these studies in preparation for submission for a BLA to regulatory agencies.
~~Immune Monitoring~~
~~We believe that understanding the status of an individual’s~~ immune system to stop unwanted attacks on self or transplanted tissues. Apoptosis is ~~key~~a natural process used by the body to ~~developing~~clear dying cells and administering immunotherapies such as ADi™. We have secured an exclusive worldwide license for commercializing a technology platform named Aditxt Immune Monitor™ (AiM™), which provides a personalized comprehensive profileto allow recognition and tolerance to self-tissues. ADI triggers this process by enabling the cells of the immune ~~system. It~~system to recognize the targeted tissues as “self.” Conceptually, it is ~~intended~~designed to be informative for individual immune responses to viruses, bacterial antigens, peptides, drugs, bone marrow and solid organ transplants, and cancer. It has broad applicability to many other agents of clinical interest impactingretrain the immune system ~~including those not yet identified such as future infectious agents.~~
~~AiM™ is being designed~~ to ~~allow individuals~~accept the tissues, similar to ~~understand, manage and monitor their~~how natural apoptosis reminds our immune ~~profiles in order~~system to be ~~informed about attacks on or by their immune system. We believe AiM™ can also assist~~tolerant to our own “self” tissues.
While various groups have promoted tolerance through cell therapies and ex vivo manipulation of patient cells (i.e., takes place outside the ~~medical community~~body), to our knowledge, we will be unique in ~~anticipating possible immune responses and reactions~~our approach of using in-body induction of apoptosis to ~~viruses, bacteria, allergens and transplanted organs. It can be useful in anticipating attacks on the body by having the ability~~promote tolerance to determine its potential response and for developing a plan to deal with an undesirable reaction by the immune system. Its advantages include the ability to provide a simple, rapid, accurate, high throughput, single platform assay that can be multiplexed to determine the immune status with respect to several factors simultaneously, in 3-16 hours, as well as detect antigen and antibody in a single test (i.e. infectious, recovered, immune).specific tissues. In addition, ~~it can determine and differentiate between various types~~ADI treatment itself will not require additional hospitalization but only an injection of ~~cellular and humoral immune responses (T and B cells). It also provides for simultaneous monitoring of cell activation and levels of cytokine release (i.e., cytokine storms).~~
We plan to utilize AiM™ in our upcoming clinical trials to monitor subjects’ immune response before, during and after ADi™ drug administration. We are also evaluating plans to obtain FDA approval for AiM™’s use as a clinical assay and seeking to secure manufacturing, marketing and distribution partnerships for application in the Infectious Diseases market, by end of 2020. To obtain FDA approval to use AiM™ as a clinical assay, we plan to conduct validation studies comparing AiM™ to other immunological tests to demonstrate reproducibility of data and to demonstrate the sensitivityminute amounts of the ~~assays for use~~therapeutic drug into the skin.
Moreover, preclinical studies have demonstrated that ADI treatment significantly and substantially prolongs graft survival, in ~~different indications (e.g., detection of antigens present in infectious agents or antibodies against infectious agents). We believe that these data will show AiM™’s ability~~addition to multiplex in two ways using a single assay: (i) evaluating the immune response to multiple antigens (from different infectious agents) and (ii) measuring quantities of multiple cytokines. Furthermore, we believe that the additional validation studies will demonstrate AiM™’s ability to measure the presence of several antibody isotypes against several antigens in a single reaction. Our plan is to submit a 510(K) application to the FDA after successful completion of these studies. We have engaged consultants for our communications and submissions to the FDA. Beyond 2020, we plan to develop AiM™ for applications in additional markets such as Organ Rejection, Allergies, Drug/Vaccine Response, and Disease Susceptibility.
successfully “reversing” other established immune-mediated inflammatory processes.
~~-16-~~
~~License Agreement with Loma Linda University~~
~~On March 8, 2018, we entered into an Assignment Agreement (the “Assignment Agreement”) with Sekris Biomedical, Inc. (“Sekris”). Sekris was a party to a~~ License Agreement with Loma Linda University (“LLU”), entered into and made effective on May 25, 2011, and amended on June 24, 2011, July 16, 2012 and December 27, 2012 (the “Original Agreement,” and together with the Assignment Agreement, the “Sekris Agreements”). Pursuant to the Assignment Agreement, Sekris transferred and assigned all of its rights and obligations in and to and liabilities under the Original Agreement, of whatever kind or nature, to us. In exchange, on March 8, 2018, we issued a warrant to Sekris to purchase up to 500,000 shares of our common stock (the “Sekris Warrant”). The warrant was immediately exercisable and has an exercise price of $4.00 per share. The expiration date of the warrant is March 8, 2023.
On March 15, 2018, we entered into a ~~LLU~~ License Agreement ~~directly~~ with ~~Loma Linda University,~~LLU, which ~~amends and restates the Sekris Agreements.~~
was subsequently amended on July 1, 2020. Pursuant to the LLU License Agreement, we obtained the exclusive royalty-bearing worldwide license ~~in and~~ to all intellectual property, including patents, technical information, trade secrets, proprietary rights, technology, know-how, data, formulas, drawings, and specifications, owned or controlled by LLU and/or any of its affiliates (the “LLU Patent and Technology Rights”) and related to therapy for immune-mediated inflammatory diseases (the ~~ADi™~~ADI™ technology). We refer you to the section titled “Our Business—Intellectual Property—Patent Rights” for a summary of the patents and patent applications that we licensed from LLU pursuant to the LLU License Agreement. In consideration for the LLU License Agreement, we issued 25,000 shares of common stock to LLU.
PEARSANTA, INC.
Formed in January 2023, our subsidiary Pearsanta™, Inc. (“Pearsanta”) seeks to take personalized medicine to a whole new level by delivering “Health by the Numbers.” Since its founding, Pearsanta has been building the platform for enabling our vision of lab quality testing, anytime, anywhere. Our plan for Pearsanta’s platform is for it to be the transactional backbone for sample collection, sample processing (on- and off-site), and reporting. This will require the development and convergence of multiple components developed by Pearsanta, or through transactions with third parties, including collection devices, “lab-on-a-chip” technologies, Lab Developed Test (LDT) assays, a data-driven analysis engine, and telemedicine. According to a comprehensive research report by Market Research Future, the clinical and consumer diagnostic market is estimated to hit $429.3 billion by 2030.
28

~~Pursuant~~
We believe that timely and personalized testing enables far more informed treatment decisions. Pearsanta’s platform is being developed as a seamless digital healthcare solution. This platform will integrate at-location sample collection, Point-of-Care (“POC”) and LDT assays, and an analytical reporting engine, with telemedicine-enabled visits with licensed physicians to review test results and, if necessary, order a prescription. Pearsanta’s goal of extending its platform to enable consumers to monitor their health more proactively as the ~~LLU License Agreement, we~~goal is to provide a more complete picture about someone’s dynamic health status, factoring in genetic makeup and their response to medication. The POC component of Pearsanta would enable diagnostic testing at-home, at work, in pharmacies, and more to generate results quickly so that an individual can access necessary treatment faster. With certain infections, prescribing the most effective treatment according to one’s numbers can prevent hospital emergency room admissions and potentially life-threatening consequences.
Examples of indication-focused tests for the Test2Treat platform will include the evaluation for advanced urinary tract infections (“UTIs”), COVID-19/flu/respiratory syncytial virus, sexually transmitted infections, gut health, pharmacogenomics (i.e., how your genes affect the way your body responds to certain therapeutics), and sepsis. We believe that these offerings are ~~required~~novel and needed as the current standard of care using broad spectrum antibiotic treatment can be ineffective and potentially life-threatening. For example, improperly prescribed antibiotics may approach 50% of outpatient cases. Further, according to ~~pay~~ an ~~annual license fee~~article published in Physician’s Weekly, only 1% of board-certified critical care medicine physicians are trained in infectious disease.
Licensed Technologies – AditxtScore^TM
We intend to ~~LLU. Also,~~sublicense to Pearsanta an exclusive worldwide sub-license for commercializing the AditxtScore™ technology which provides a personalized comprehensive profile of the immune system. AditxtScore is intended to detect individual immune responses to viruses, bacteria, peptides, drugs, supplements, bone marrow and solid organ transplants, and cancer. It has broad applicability to many other agents of clinical interest impacting the immune system, including those not yet identified such as emerging infectious agents.
AditxtScore is being designed to enable individuals and their healthcare providers to understand, manage and monitor their immune profiles and to stay informed about attacks on or by their immune system. We believe AditxtScore can also assist the medical community and individuals by being able to anticipate the immune system’s potential response to viruses, bacteria, allergens, and foreign tissues such as transplanted organs. This technology may be able to serve as a warning signal, thereby allowing for more time to respond appropriately. Its advantages include the ability to provide simple, rapid, accurate, high throughput assays that can be multiplexed to determine the immune status with respect to several factors simultaneously, in approximately 3-16 hours. In addition, it can determine and differentiate between distinct types of cellular and humoral immune responses (e.g., T and B cells and other cell types). ~~We agreed to pay LLU $455,000 in July 2020 in payment~~It also provides for simultaneous monitoring of ~~outstanding milestone payments~~cell activation and ~~license fees.~~ levels of cytokine release (i.e., cytokine storms).
We are ~~also required~~actively involved in the regulatory approval process for AditxtScore assays for clinical use and securing manufacturing, marketing, and distribution partnerships for application in the various markets. To obtain regulatory approval to ~~pay~~use AditxtScore as a clinical assay, we have conducted validation studies to ~~LLU milestone payments~~evaluate its performance in ~~connection with certain development milestones. Specifically, we are required~~detection of antibodies and plan to ~~make the following milestone payments: $175,000 on March 31, 2022; $100,000 on March 31, 2024; $500,000 on March 31, 2026; and $500,000 on March 31, 2027. Additionally, as consideration~~continue conducting additional validation studies for prior expenses incurred by LLU to prosecute, maintain and defend the LLU Patent and Technology Rights, we are obligated to make the following payments to LLU:, $70,000 due at the end of December 2018, and a final payment of $60,000 due at the end of March 2019. We are required to defend the LLU Patent and Technology Rights during the termnew applications in autoimmune diseases.
Advantages
The sophistication of the LLU License Agreement. Additionally, we will owe royalty payments of (i) 1.5% of Net Product Sales and Net Service Sales on any Licensed Products (defined as any finished pharmaceutical products which utilizesAditxtScore technology includes the LLU Patent and Technology Rights in its development, manufacture or supply), and (ii) 0.75% of Net Product Sales and Net Service Sales for Licensed Products and Licensed Services not covered by a valid patent claim for technology rights and know-how for a three (3) year period beyond the expiration of all valid patent claims. We also are required to produce a written progress report to LLU, discussing our development and commercialization efforts, within 45 days following the end of each year. All intellectual property rights in and to LLU Patent and Technology Rights shall remain with LLU (other than improvements developed by or on our behalf).following:
● greater sensitivity/specificity.
● 20-fold higher dynamic range, greatly reducing signal to noise compared to conventional assays.
● ability to customize assays and multiplex a large number of analytes with speed and efficiency.
● ability to test for cellular immune responses (i.e., T and B cells and cytokines).
● proprietary reporting algorithm.
29

The LLU License Agreement shall terminate on the last day that a patent granted in to us by LLU is valid and enforceable or the day that the last patent application licensed to us is abandoned. The LLU License Agreement may be terminated by mutual agreement or by us upon 90 days written notice to LLU. LLU may terminate the LLU License Agreement in the event of (i) non-payments or late payments of royalty, milestone and license maintenance fees not cured within 90 days after delivery of written notice by LLU, (ii) a breach of any non-payment provision (including the provision that requires us to meet certain deadlines for milestone events (each, a “Milestone Deadline”)) not cured within 90 days after delivery of written notice by LLU and (iii) LLU delivers notice to us of three or more actual breaches of the LLU License Agreement by us in any 12-month period. Additional Milestone Deadlines include: (i) the requirement to have regulatory approval of an IND application to initiate a first-in-human clinical trials on or before March 31, 2020, (ii) the completion of first-in-human (phase I/II) clinical trials by March 31, 2022, (iii) the completion of Phase III clinical trials by March 31, 2024 and (iv) biologic licensing approval by the FDA by March 31, 2025.
License Agreement with Leland Stanford Junior University (“Stanford”)
On February 3, 2020, we entered into an exclusive license agreement (the “February 2020 License Agreement”) with Stanford with regard to a patent concerning a method for detection and measurement of specific cellular responses. Pursuant to the February 2020 License Agreement, we received an exclusive worldwide license to Stanford’s patent with regard to use, import, offer, and sale of Licensed Products (as defined in the agreement). The license to the patented technology is exclusive, including the right to sublicense, beginning on the effective date of the agreement, and ending when the patent expires. Under the exclusivity agreement, we acknowledged that Stanford had already granted a non-exclusive license in the Nonexclusive Field of Use, under the Licensed Patents in the Licensed Field of Use in the Licensed Territory (as those terms are defined in the ~~February~~“February 2020 License Agreement”). However, Stanford agreed not to ~~not~~ grant further licenses under the Licensed Patents in the Licensed Field of Use in the Licensed Territory.
~~-17-~~
~~We were obligated~~ On December 29, 2021, we entered into an amendment to pay a fee of $25,000 to Stanford within 60 days of February 3, 2020. We also issued 18,750 shares of the Company’s common stock to Stanford. An annual licensing maintenance fee is payable by us on the first anniversary of the February 2020 License Agreement which extended our exclusive right to license the technology deployed in ~~the amount of $40,000 for 2021 through 2024~~ AditxtScore^TMand ~~$60,000~~securing worldwide exclusivity in starting in 2025 until the license expires upon the expiration of the patent. The Company will pay milestone fees of $50,000 on the first commercial sales of a licensed product and $25,000 at the beginning of any clinical study for regulatory clearance of an ~~in vitro~~ diagnostic product developed and a potential licensed product. We are also required to: (i) provide a listing of the management team or a schedule for the recruitment of key management positions by March 31, 2020 (which has been completed), (ii) provide a business plan covering projected product development, markets and sales forecasts, manufacturing and operations, and financial forecasts until at least $10,000,000 in revenue by June 30, 2020, (iii) conduct validation studies by September 30, 2020, (iv) hold a pre-submission meeting with the FDA by September 30, 2020, (v) submit a 510(k) application to the FDA by December 31, 2020, (vi) obtain FDA approval by December 31, 2021, (vii) complete a prototype assay kit by December 31, 2021 and (viii) have a written agreement with Stanford on further development and commercialization milestones for specificall fields of use ~~by December 31, 2021.~~of the licensed technology.
~~In addition~~ADIVIR, INC.
Formed in April of 2023, Adivir™, Inc., is Aditxt’s most recently formed wholly owned subsidiary, dedicated to the ~~annual license maintenance fees outlined above,~~clinical and commercial development efforts of innovative antiviral products, which have the potential to address a wide range of infectious diseases, including those that currently lack viable treatment options.
Background
On April 18, 2023, we entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”) with Cellvera Global Holdings LLC (“Cellvera Global”), Cellvera Holdings Ltd. (“BVI Holdco”), Cellvera, Ltd. (“Cellvera Ltd.”), Cellvera Development LLC (“Cellvera Development” and together with Cellvera Global, BVI Holdco, Cellvera Ltd. and Cellvera Development (the “Sellers”), AiPharma Group Ltd. (“Seller Owner” and collectively with the Sellers, “Cellvera”), and the legal representative of Cellvera, pursuant to which, the Company will ~~pay Stanford royalties on Net Sales (as such term is~~purchase Cellvera’s 50% ownership interest in G Response Aid FZE (“GRA”), certain other intellectual property and all goodwill related thereto (the “Acquired Assets”). Unless expressly stated otherwise herein, capitalized terms used but not defined herein have the meanings ascribed to them in the ~~February 2020 License Agreement) during~~Asset Purchase Agreement. Pursuant to the Asset Purchase Agreement, the consideration for the Acquired Assets consists of (A) $24.5 million, comprised of: (i) the forgiveness of the Company’s $14.5 million loan to Cellvera Global, and (ii) approximately $10 million in cash, and (B) future revenue sharing payments for a term of seven years. GRA holds an exclusive, worldwide license for the ~~agreement~~antiviral medication, Avigan® 200mg, excluding Japan, China and Russia. The other 50% interest in GRA is held by Agility, Inc. (“Agility”).
Additionally, upon the closing, the Share Exchange Agreement previously entered into as ~~follows: 4% when Net Sales~~of December 28, 2021, between Cellvera Global Holdings, LLC f/k/a AiPharma Global Holdings, LLC (together with other affiliates and subsidiaries) and the Company, and all other related agreements will be terminated.
The obligations of the Company to consummate the Closing under the Asset Purchase Agreement are ~~below~~subject to the satisfaction or ~~equal~~waiver, at or prior to ~~$5 million annually~~the Closing of certain conditions, including but not limited to, the following:
(i) Satisfactory completion of due diligence;
(ii) Completion by the Company of financing sufficient to consummate the transactions contemplated by the Asset Purchase Agreement;
(iii) Receipt by the Company of all required Consents from Governmental Bodies for the Acquisition, including but not limited to, any consents required to complete the transfer and assignment of Cellvera’s membership interests in GRA;

30
(iv) Receipt of executed payoff letters reflecting the amount required to be fully pay all of each of Seller’s and Seller Owner’s Debt to be paid at Closing;
(v) Receipt by the Company of a release from Agility;
(vi) Execution of an agreement acceptable to the Company with respect to the acquisition by the Company of certain intellectual property presently held by a third party;
(vii) Execution of an amendment to an asset purchase agreement previously entered into by Cellvera with a third party that effectively grants the Company the rights to acquire the intellectual property from the third party under such agreement;
(viii) Receipt of a fairness opinion by the Company with respect to the transactions contemplated by the Asset Purchase Agreement; and
(ix) Receipt by the Company from the Seller Owner of written consent, whether through its official liquidator or the Board of Directors of Seller Owner, to the sale and purchase of the Acquired Assets and Assumed Liabilities pursuant to the Assert Purchase Agreement.
There can be no assurance that the conditions to closing will be satisfied or ~~6% when Net Sales are above $5 million annually. The February 2020 License Agreement may~~that the proposed acquisition will be ~~terminated upon~~completed as proposed or at all.
Our commitment to building our ~~election on at least 30 days advance notice~~antiviral portfolio is strategic and timely. We believe that there has never has there been a more important time to ~~Stanford,~~address the growing global need to uncover new treatments or ~~by Stanford if we: (i) are delinquent on any report or payment; (ii) are not diligently~~commercialize existing ones that treat life-threatening global viral infections.
Our Team
Aditxt has assembled an entrepreneurial team of experts from a variety of different business, engineering, and scientific fields, and commercial backgrounds, with collective experience that ranges from founding startup innovation companies, to developing and ~~commercializing Licensed Product; (iii) miss certain performance milestones; (iv) are~~marketing biopharmaceutical and diagnostic products, to designing clinical trials, and management of private and public companies. We have deep experience in ~~breach of any provision of~~identifying and accessing promising health innovations and developing them into products and services with the ~~February 2020 License Agreement; or (v) provide any false report~~ability to ~~Stanford. Should any events in~~scale. We understand the ~~preceding sentence occur, we have a thirty (30) day cure period to remedy such violation.~~capital markets, both public and private, as well as M&A and facilitating complex IPOs.
Going Concern
~~The Company was~~We were incorporated on September 28, 2017 and ~~has~~have not generated significant revenues to date. During the ~~six~~nine months ended ~~June~~September 30, ~~2020 the Company~~2023 we had a net loss of ~~$1,723,680~~$21,412,626 and cash of $1,651,354 as of September 30, 2023. The Company will require significant additional capital ~~in order~~ to operate in the normal course of business and fund clinical studies in the long-term. As a result of the ~~IPO,~~September 2022 Offering, the ~~Company~~April Purchase Agreement, and the August Purchase Agreement, we received net proceeds of approximately ~~$9.5 million subsequent to~~$28,000,000 during the ~~period presented. The Company believes~~last twelve months. We believe that the remaining funds ~~raised by the IPO~~on hand will not be sufficient to fund ~~the Company’s operation~~our operations for ~~at least~~ the next 12 ~~months. As a result, these conditions have alleviated the~~months and such creates substantial doubt ~~regarding~~about our ability to continue as a going concern beyond one year.
Financial Results
We have a limited operating history. Therefore, there is limited historical financial information upon which to base an evaluation of our performance. Our prospects must be considered in light of the uncertainties, risks, expenses, and difficulties frequently encountered by companies in their early stages of operations. Our condensed consolidated financial statements as of ~~June~~September 30, ~~2020,~~2023, show a net loss of ~~$1,723,680.~~$20,412,626. We expect to incur additional net expenses over the next several years as we continue to maintain and expand our existing operations. The amount of future losses and when, if ever, we will achieve profitability are uncertain.
On July 2, 2020, the Company completed its initial public offering (“IPO”). In connection therewith, the Company issued 1,226,668 Units, excluding the underwriters’ overallotment, at an offering price of $9.00 per Unit, resulting in gross proceeds of approximately $11.0 million. The Units issued in the IPO consisted of one share of common stock, one Series A warrant, and one Series B warrant. The Series A warrants have an exercise price of $9.00 and a term of 5 years. The Series B warrants have exercise price of $11.25 and a term of 5 years. Substantially all of the Series B warrants issued in the IPO as part of the Units have been exercised pursuant to a cashless provision therein.
~~-18-~~
31

Results of Operations
Results of operations for the three months ended ~~June~~September 30, ~~2020~~2023 and 2022
We generated revenue of $124,486 and $323,125 for the three months ended September 30, 2023 and 2022, respectively. Cost of sales for the three months ended September 30, 2023 and 2022 was $106,922 and $233,684, respectively.
During the three months ended ~~June~~September 30, ~~2020,~~2023, we incurred a loss from operations of ~~$398,479.~~$8,095,209. This is due to general and administrative expenses of ~~$352,338,~~$7,169,863, which includes ~~$160,329~~approximately $3,351,000 in payroll expenses, $1,128,000 in professional fees, and $103,031 in stock-based ~~compensation, research~~compensation. Research and development ~~of $28,294,~~expenses were $898,724, which includes $151,605 in consulting expenses and ~~sales~~$49,209 in stock-based compensation. Sales and marketing expenses ~~of $2,848. The $28,294~~were $44,186, which includes $1,752 in ~~research and development is comprised of $625 in licensing fees, $13,500 in product development, and $14,169 in other research and development expense.~~stock-based compensation.

During the three months ended ~~June~~September 30, ~~2019,~~2022, we incurred a loss from operations of ~~$2,555,525.~~$5,392,164. This is due to general and administrative expenses of ~~$2,511,438,~~$3,919,618, which includes ~~$2,098,759~~$461,492 in stock-based ~~compensation,~~compensation; research and development of ~~$43,978,~~$1,570,540, which includes $170,066 in stock-based compensation, and sales and marketing expenses of ~~$109.~~$(8,553), which includes $0 in stock-based compensation. The ~~$43,978~~$1,570,540 in research and development is mainly comprised of ~~$15,181~~$974,982 in ~~licensing fees, $13,500~~compensation and $248,012 in ~~product development and $15,297 in other~~consulting expenses, offset by a one-time adjustment to research and development ~~expense.~~purchases. During the quarter, the Company transitioned from purchasing certain inventory items to internally manufacturing these items.
The decrease in expenses during the three months ended September 30, 2023 compared to the three months ended September 30, 2022 was due to decreased research and development spend and the termination of a sales and marketing vendor.
Results of operations for the ~~six~~nine months ended ~~June~~September 30, ~~2020~~2023 and 2022
We generated revenue of $563,879 and $748,119 for the nine months ended September 30, 2023 and 2022, respectively. Cost of sales for the nine months ended September 30, 2023 and 2022 was $470,969 and $596,613, respectively.
During the ~~six~~nine months ended ~~June~~September 30, ~~2020,~~2023, we incurred a loss from operations of ~~$1,455,277.~~$18,111,541. This is due to general and administrative expenses of ~~$1,208,765,~~$15,209,789. This includes approximately $7,682,000 in payroll expenses, $3,063,000 in professional fees, and $484,502 in stock-based compensation. Research and development expenses were $2,771,100, which includes ~~$689,766~~$1,034,698 in consulting expenses and $165,382 in stock-based ~~compensation, research and development of $228,665, and sales~~compensation. Sales and marketing expenses ~~of $2,848. The $228,665~~were $223,562, which includes $6,787 in ~~research and development is comprised of $126,670 in licensing fees, $27,000 in product development, and $74,995 in other research and development expense.~~stock-based compensation.
During the ~~six~~nine months ended ~~June~~September 30, ~~2019,~~2022, we incurred a loss from operations of ~~$3,800,214.~~$17,280,052. This is due to general and administrative expenses of ~~$3,711,221,~~$12,332,728, which includes ~~$2,822,367~~$1,288,829 in stock-based compensation, research and development of ~~$88,846,~~$4,186,842, which includes $473,593 in stock-based compensation, and sales and marketing expenses of ~~$147.~~$911,988, which includes $754,699 in stock-based compensation. The ~~$88,846~~$4,186,842 in research and development is mainly comprised of ~~$15,181~~$1,350,384 in ~~licensing fees, $27,000~~consulting expenses, and $2,517,836 in ~~product development and $46,665 in other~~compensation offset by a one-time adjustment to research and development ~~expense.~~purchases. During the quarter, the Company transitioned from purchasing certain inventory items to internally manufacturing these items.
The decrease in expenses during the nine months ended September 30, 2023 compared to the three months ended September 30, 2022 was due to decreased research and development spend and the termination of a sales and marketing vendor.
Liquidity and Capital Resources
We have incurred substantial operating losses since inception and expect to continue to incur significant operating losses for the foreseeable future and may never become profitable. As of ~~June~~September 30, ~~2020,~~2023, we had an accumulated deficit of ~~approximately $13.5 million. The Company~~$116,620,157. We had a working capital ~~deficit~~ of ~~$4,254,802~~$(7,815,514) as of ~~June~~September 30, ~~2020.~~2023. During the nine months ended September 30, 2023, we purchased $14,407 in fixed assets, for which we made cash payments of $14,407. Of the $14,407, $12,356 of these purchased fixed assets were lab equipment and $2,051 was for computers.
32

Our condensed consolidated financial statements have been prepared assuming that we will continue as a going concern.
~~The Company has~~We have funded ~~its~~our operations from proceeds from the sale of equity and debt securities. On July 2, 2020, ~~the Company~~we completed ~~its~~our IPO and raised approximately $9.5 million in net proceeds. ~~The Company~~At the time of the IPO, we believed that these funds ~~will~~would be sufficient to fund ~~the Company’s~~our operations for the foreseeable future. ~~The~~
On September 10, 2020, we completed a follow-on public offering. In connection therewith, we issued 1,200 units, or Follow-On Units, excluding the underwriters’ option to cover overallotments, at an offering price of $8,000.00 per Follow-On Unit, resulting in gross proceeds of approximately $9.6 million.
On January 25, 2021, the Company ~~may need to raise additional funding through strategic relationships, public or private equity or debt financings, grants or other arrangements to develop and seek regulatory approvals~~entered into a securities purchase agreement with an institutional accredited investor (the “Investor”) for the sale of a $6,000,000 senior secured convertible note (the “Convertible Note”). The Convertible Note had a term of 24 months, was originally convertible at a price of $8,000.00 per share and was issued at an original issuance discount of $1,000,000. On August 30, 2021, the Company entered into a defeasance and waiver agreement with the Investor, pursuant to which the Noteholder has agreed in exchange for (a) a cash payment by the Company to the Investor of $1.2 million (the Cash Payment”), (b) a waiver, in part of the conversion price adjustment provision such that the January 2021 Note shall be convertible into 2,401 shares of common stock (without giving effect to the conversion notice received by the company form the Noteholder prior to the date hereof totaling (503 shares) (the “Shares”), and (c) a voluntary and permanent reduction by the Company of the exercise price of the warrant to purchase 400 shares of the common stock of the Company (the “January 2021 Warrant”) to $5,060 per share. As of December 31, 2022, the outstanding principle of the convertible note had been converted to 2,401 shares of common stock.
On August 30, 2021, the Company completed a registered direct offering and raised approximately $10.1 million in net proceeds.
On October 20, 2021, the Company completed a public offering for net proceeds of $3.8 million. As part of this offering, we issued 1,417 shares of the Company’s ~~existing~~common stock
On December 6, 2021, the Company completed a public offering for net proceeds of $16.0 million. As part of this offering, we issued 4,123 units consisting of shares of the Company’s common stock and ~~new product candidates. If~~warrant to purchase shares of the Company’s common stock and 4,164 pre-funded warrants. The warrant issued as part of the units had an exercise price of $2,300.00 and the prefunded warrants had an exercise price of $0.001.
On September 20, 2022, the Company completed a public offering for net proceeds of $18.1 million (the “September 2022 Offering”). As part of the September 2022 Offering, we issued 30,608 of shares of the Company’s common stock, pre-funded warrants to purchase 52,725 shares of the Company’s common stock and warrants to purchase 83,333 shares of the Company’s common stock. The warrants have an exercise price of $240.00 and the pre-funded warrants have an exercise price of $0.004.
On April 20, 2023, the Company entered into a securities purchase agreement (the “Purchase Agreement”) with an institutional investor, pursuant to which the Company agreed to sell to such ~~funding is not available or not available~~investor pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 39,634 shares of common stock of the Company (the “Common Stock”) at a purchase price of $48.76 per Pre-Funded Warrant. Concurrently with the sale of the Pre-Funded Warrants, pursuant to the Purchase Agreement in a concurrent private placement, for each Pre-Funded Warrant purchased by the investor, such investor received from the Company an unregistered warrant (the “Warrant”) to purchase two shares of Common Stock. The warrants have an exercise price of $34.40 per share and are exercisable for a three-year period. In addition, the Company issued a warrant to the placement agent to purchase up to 2,378 shares of common stock at an exercise price of $61.00 per share.
On August 31, 2023, the Company entered into a securities purchase agreement (the “August Purchase Agreement”) with an institutional investor for the issuance and sale in a private placement (the “Private Placement”) of (i) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 1,000,000 shares of the Company’s common stock at an exercise price of $0.001 per share, and (ii) warrants (the “Common Warrants”) to purchase up to 1,000,000 shares of the Company’s Common Stock at an exercise price of $10.00 per share. The Private Placement closed on ~~terms acceptable~~September 6, 2023. The net proceeds to the Company from the ~~Company’s current development plan~~Private Placement were approximately $9 million, after deducting placement agent fees and ~~plans~~expenses and estimated offering expenses payable by the Company. The Company utilized net proceeds received from the Private Placement for ~~expansion~~(i) payment of ~~its general~~approximately $3.1 million in outstanding obligations, (ii) repayment of approximately $0.4 million of outstanding debt, and ~~administrative infrastructure may be curtailed.~~(iii) continuing operating expenses and working capital.
~~-19-~~
33

We ~~may~~will need ~~to raise~~ significant additional capital to continue to fund our operations and the clinical ~~trials.~~trials for our product candidates. We may seek to sell common stock, preferred stock or convertible debt securities, enter into a credit facility or another form of third-party funding or seek other debt financing. In addition, we may seek to raise cash through collaborative agreements or from government grants. The sale of equity and convertible debt securities may result in dilution to our stockholders and certain of those securities may have rights senior to those of our common shares. If we raise additional funds through the issuance of preferred stock, convertible debt securities, or other debt financing, these securities or other debt could contain covenants that would restrict our operations. Any other third-party funding arrangement could require us to relinquish valuable rights.
The source, timing, and availability of any future financing will depend principally upon market conditions, and, more specifically, on the progress of our clinical development program. Funding may not be available when needed, at all, or on terms acceptable to us. Lack of necessary funds may require us to, among other things, delay, scale back or eliminate expenses including some or all of our planned development, including our clinical trials. While ~~the Company~~we may need to raise funds in the future, we believe the ~~Company believed its~~ current cash reserves should be sufficient to fund ~~the Company’s~~our operation for the foreseeable future. Because of these factors, ~~the Company believes~~we believe that this ~~alleviates the issues~~creates doubt about ~~the Company’s~~our ability to continue as a going concern.
Contractual Obligations
The following table shows our contractual obligations as of September 30, 2023:
Payment Due by Year
Total 2023 2024 2025 2026
Lease $ 2,425,449 $ 285,991 $ 1,004,982 $ 710,546 $ 423,930
Critical Accounting Polices and Estimates
Our condensed consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States. The preparation of our condensed consolidated financial statements and related disclosures requires us to make estimates, assumptions and judgments that affect the reported amount of assets, liabilities, revenue, costs and expenses, and related disclosures. We believe that of our critical accounting policies described under the heading “Management’s Discussion and Analysis of Financial Condition and Plan of Operations—Critical Accounting Policies” in ~~the Company’s~~our Prospectus, dated ~~June 29,~~September 1, 2020, filed with the SEC pursuant to Rule 424(b), ~~the~~are critical to fully understanding and evaluating our financial condition and results of operations. The following involve the most judgment and complexity:
● Research and development
● Stock-based compensation expense
● ~~Fair value of common stock~~
Accordingly, we believe the policies set forth above are critical to fully understanding and evaluating our financial condition and results of operations. If actual results or events differ materially from the estimates, judgments and assumptions used by us in applying these policies, our reported financial condition and results of operations could be materially affected.
Off-Balance Sheet Arrangements
We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.
~~-20-~~
JOBS Act
On April 5, 2012, the JOBS Act was enacted. Section 107 of the JOBS Act provides that an “emerging growth company” can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act, for complying with new or revised accounting standards. In other words, an “emerging growth company” can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies.
34

We
When favorable, we have chosen to take advantage of the extended transition periods available to emerging growth companies under the JOBS Act for complying with new or revised accounting standards until those standards would otherwise apply to private companies provided under the JOBS Act.
We are in the process of evaluating the benefits of relying on other exemptions and reduced reporting requirements provided by the JOBS Act. Subject to certain conditions set forth in the JOBS Act, as an “emerging growth company,” we intend to rely on certain of these exemptions, including without limitation, (i) providing an auditor’s attestation report on our system of internal controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act and (ii) complying with any requirement that may be adopted by the Public Company Accounting Oversight Board (“PCAOB”) regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements, known as the auditor discussion and analysis. We will remain an “emerging growth company” until the earliest of (i) the last day of the fiscal year in which we have total annual gross revenues of $1.07 billion or more; (ii) the last day of our fiscal year following the fifth anniversary of the date of the completion of ~~this offering;~~our IPO (December 31, 2025); (iii) the date on which we have issued more than $1 billion in nonconvertible debt during the previous three years; or (iv) the date on which we are deemed to be a large accelerated filer under the rules of the ~~Securities and Exchange Commission.~~SEC.
Recently Issued and Adopted Accounting Pronouncements
See Note 3 - Summary of Significant Accounting Policies to the accompanying condensed consolidated financial statements for a description of other accounting policies and recently issued accounting pronouncements.
Recent Developments
See Note 12 – Subsequent Event to the accompanying condensed consolidated financial statements for a description of material recent developments.
Item 3. Quantitative and Qualitative Disclosures About Market Risk.
~~The Company is~~We are not required to provide the information required by this Item as ~~it is~~we are a “smaller reporting company,” as defined in Rule ~~229.10(f)(1).~~12b-2 of the Exchange Act.
Item 4. Controls and Procedures.
Disclosure Controls and Procedures
In accordance with Rules 13a-15(b) and 15d-15(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), we, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) and Rule 15d-15(e) of the Exchange Act) as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on the foregoing, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were (a) designed to ensure that the information we are required to disclose in our reports under the Exchange Act is recorded, processed, and reported in an accurate manner and on a timely basis and the information that we are required to disclose in our Exchange Act reports is accumulated and communicated to management to permit timely decisions with respect to required disclosure and (b) operating in an effective manner.
Change in Internal Control Over Financial Reporting
No change occurred in our internal control over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) of the Exchange Act) during the quarter ended ~~June~~September 30, ~~2020~~2023 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
~~-21-~~
35

PART II - OTHER INFORMATION
Item 1. Legal Proceedings
From time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business.
The Company, Amro Albanna, our President and Chief Executive Officer, and Dr. Shahrokh Shabahang, our Chief Innovation Officer, have been named as cross-defendants in a counterclaim filed by Christopher Sechrist in an action entitled Shahrokh Shabahang v. Christopher Sechrist, San Bernardino County Superior Court Case No. CIVDS1831323. In a cross-complaint, Mr. Sechrist contends that he was a partner in a dental practice with Dr. Shabahang, and that disputes arose as between those partners. Neither the Company nor Mr. Albanna were partners in, or otherwise have an interest in, the dental practice. Notwithstanding, and seemingly based solely on the fact that Dr. Shabahang became the Chief Innovation Officer for the Company, Mr. Sechrist has brought claims against the Company and Mr. Albanna. Both the Company and Mr. Albanna believe that the Counterclaims filed by Mr. Sechrist have no factual or legal merit, and they intend to vigorously defend themselves in the action and to seek a dismissal of the case as against them as soon as possible. On May 26, 2020, Mr. Sechrist filed a request for dismissal as to the Company and Mr. Albanna with the Superior Court of California, County of San Bernardino, San Bernardino District. The clerk of the court entered the dismissal with prejudice on May 26, 2020.
Our CEO, Amro Albanna, is a party to litigation matters unrelated to the Company or any of its properties. Such litigations relate to Innovation Economy Corporation (IEC), a company in which Mr. Albanna served as the CEO and a Director from 2010 until 2017, and its wholly-owned subsidiaries (Innovation Economy Corporation d/b/a ieCrowd). The first litigation (ieCrowd v. Kim, et. al, Superior Court, Riverside County) was originally commenced by IEC and its subsidiary after Mr. Albanna was no longer affiliated with IEC, against certain third-party defendants based upon claims related to their misconduct and mismanagement. Such defendants subsequently brought a countersuit against IEC and its subsidiary, in which they named Mr. Albanna and others as defendants, alleging that they were misled to invest in IEC and its subsidiary based upon misrepresentations by, among others, Mr. Albanna. The cases have now been consolidated. Mr. Albanna believes that the counteraction commenced by the third parties against him is without merit and intends to defend himself. The second matter (Calabria v. ieCrowd) was commenced by Calabria Ventures more than 2 years after Mr. Albanna was no longer affiliated with IEC, related to uncollected rent. Mr. Albanna believes that the action commenced against him is without merit and intends to defend himself. IEC (either directly or through its Director and officer insurance policy) has covered all related legal costs to date.
Item 1A. Risk Factors
Our business, financial condition, results of operations, and cash flows may be impacted by a number of factors, many of which are beyond our control, including those set forth below and in our ~~Prospectus,~~most recent Annual Report on Form 10-K and in our other filings with the SEC, the occurrence of any one of which could have a material adverse effect on our actual results.
Our financial situation creates doubt whether we will continue as a going concern.
The Company was incorporated on September 28, 2017 and through the date of this report has generated no significant revenues. For the years ended December 31, 2022 and 2021, the Company had a net loss of $27,649,876 and $46,371,364, respectively. Our condensed consolidated financial statements as of September 30, 2023, show a net loss of $21,412,626. Our cash and cash equivalents were approximately $1,651,354 as of September 30, 2023. There can be no assurances that we will be able to achieve a level of revenues adequate to generate sufficient cash flow from operations or additional financing through private placements, public offerings and/or bank financing necessary to support our working capital requirements. To the extent that funds generated from any private placements, public offerings and/or bank financing are insufficient, we will have ~~been no material changes~~to raise additional working capital. No assurance can be given that additional financing will be available, or if available, will be on acceptable terms. These conditions raise substantial doubt about our ability to continue as a going concern. If adequate working capital is not available, we may be forced to discontinue operations, which would cause investors to lose their entire investment.
If we fail to obtain the capital necessary to fund our operations, we will be unable to continue or complete our product development and you will likely lose your entire investment.
We will need to continue to seek capital from time to time to continue development of our lead drug candidate beyond our initial combined Phase I/IIa clinical trial and to acquire and develop other product candidates. Once approved for commercialization, we cannot provide any assurances that any revenues it may generate in the future will be sufficient to fund our ongoing operations.
Our business or operations may change in a manner that would consume available funds more rapidly than anticipated and substantial additional funding may be required to maintain operations, fund expansion, develop new or enhance products, acquire complementary products, business or technologies, or otherwise respond to competitive pressures and opportunities, such as a change in the regulatory environment or a change in preferred treatment modalities. In addition, we may need to accelerate the growth of our sales capabilities and distribution beyond what is currently envisioned, and this would require additional capital. However, we may not be able to secure funding when we need it or on favorable terms. We may not be able to raise sufficient funds to commercialize the product candidates we intend to develop.
If we cannot raise adequate funds to satisfy our capital requirements, we will have to delay, scale back or eliminate our research and development activities, clinical studies, or future operations. We may also be required to obtain funds through arrangements with collaborators, which arrangements may require us to relinquish rights to certain technologies or products that we otherwise would not consider relinquishing, including rights to future product candidates or certain major geographic markets. This could result in sharing revenues which we might otherwise retain for ourselves. Any of these actions may harm our business, financial condition, and results of operations.
The amount of capital we may need depends on many factors, including the progress, timing and scope of our product development programs; the progress, timing and scope of our preclinical studies and clinical trials; the time and cost necessary to obtain regulatory approvals; the time and cost necessary to further develop manufacturing processes and arrange for contract manufacturing; our ability to enter into and maintain collaborative, licensing and other commercial relationships; and our partners’ commitment of time and resources to the ~~Risk Factors previously disclosed~~development and commercialization of our products.
36
Our obligations to certain of our creditors are secured by security interests in our ~~Prospectus, except~~assets, so if we default on those obligations, our creditors could foreclose on some or all of our assets.
Our obligations to certain of our creditors are secured by security interests in our assets. As of September 30, 2023, approximately $4.0 million was owed to such secured creditors. Under such agreements, we are required to pay $201,857 on a weekly basis to such creditors. If we default on our obligations under these agreements, our secured creditors could foreclose on its security interests and liquidate some or all of these assets, which would harm our financial condition and results of operations and would require us to reduce or cease operations and possibly seek Bankruptcy Protection.
In the event we pursue Bankruptcy Protection, we will be subject to the risks and uncertainties associated with such proceedings.
In the event we file for relief under the United States Bankruptcy Code, our operations, our ability to develop and execute our business plan and our continuation as ~~noted below.~~a going concern will be subject to the risks and uncertainties associated with bankruptcy proceedings, including, among others: our ability to execute, confirm and consummate a plan of reorganization; the additional, significant costs of bankruptcy proceedings and related fees; our ability to obtain sufficient financing to allow us to emerge from bankruptcy and execute our business plan post-emergence, and our ability to comply with terms and conditions of that financing; our ability to continue our operations in the ordinary course; our ability to maintain our relationships with our consumers, business partners, counterparties, employees and other third parties; our ability to obtain, maintain or renew contracts that are critical to our operations on reasonably acceptable terms and conditions; our ability to attract, motivate and retain key employees; the ability of third parties to use certain limited safe harbor provisions of the United States Bankruptcy Code to terminate contracts without first seeking Bankruptcy Court approval; the ability of third parties to force us to into Chapter 7 proceedings rather than Chapter 11 proceedings and the actions and decisions of our stakeholders and other third parties who have interests in our bankruptcy proceedings that may be inconsistent with our operational and strategic plans. Any delays in our bankruptcy proceedings would increase the risks of our being unable to reorganize our business and emerge from bankruptcy proceedings and may increase our costs associated with the bankruptcy process or result in prolonged operational disruption for us. Also, we would need the prior approval of the bankruptcy court for transactions outside the ordinary course of business during the course of any bankruptcy proceedings, which may limit our ability to respond timely to certain events or take advantage of certain opportunities. Because of the risks and uncertainties associated with any bankruptcy proceedings, we cannot accurately predict or quantify the ultimate impact of events that could occur during any such proceedings. There can be no guarantees that if we seek Bankruptcy Protection we will emerge from Bankruptcy Protection as a going concern or that holders of our common stock will receive any recovery from any bankruptcy proceedings.
In the event we are unable to pursue Bankruptcy Protection under Chapter 11 of the United States Bankruptcy Code, or, if pursued, successfully emerge from such proceedings, it may be necessary to pursue Bankruptcy Protection under Chapter 7 of the United States Bankruptcy Code for all or a part of our businesses.
In the event we are unable to pursue Bankruptcy Protection under Chapter 11 of the United States Bankruptcy Code, or, if pursued, successfully emerge from such proceedings, it may be necessary for us to pursue Bankruptcy Protection under Chapter 7 of the United States Bankruptcy Code for all or a part of our businesses. In such event, a Chapter 7 trustee would be appointed or elected to liquidate our assets for distribution in accordance with the priorities established by the United States Bankruptcy Code. We believe that liquidation under Chapter 7 would result in significantly smaller distributions being made to our stakeholders than those we might obtain under Chapter 11 primarily because of the likelihood that the assets would have to be sold or otherwise disposed of in a distressed fashion over a short period of time rather than in a controlled manner and as a going concern.
37

~~Unfavorable global economic, business,~~We received a written notice from Nasdaq that we have failed to comply with certain listing requirements of the Nasdaq Stock Market, which could result in our Common Stock being delisted from the Nasdaq Stock Market.
On May 23, 2023, we received written notice from Nasdaq that, based upon the stockholders equity reported by the Company in its Form 10-Q for the period ended March 31, 2023, and as of March 31, 2023, the Company was no longer in compliance with Nasdaq Listing Rule 5550(b)(1), which requires a company to maintain a minimum of $2,500,000 in stockholders’ equity, a market value of listed securities of at least $35 million, or ~~political conditions~~net income from continuing operations of $500,000 in the most recently completed fiscal year or in two of the three most recently completed fiscal years (the “Continued Listing Requirements”). The May notification letter further provided that the Company has 45 calendar days, or until July 7, 2023, to submit a plan to regain compliance and if the plan is accepted by Nasdaq, an extension of up to 180 calendar days, or until November 19, 2023 to evidence compliance. On June 22, 2023, we received a letter from Nasdaq notifying the Company that it has failed to maintain compliance with the minimum bid price rule in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Rule”) as the closing price of Company’s common stock has remained below $1.00 for over 30 consecutive trading days. On June 29, 2023, we submitted an appeal to Nasdaq, which stays the delisting and suspension of our securities pending the decision of the Nasdaq Hearings Panel (the “Panel”). At the hearing, which was held on August 31, 2023, which represented the tenth trading day that the closing of the Company’s common stock was above $1.00 per share. At the hearing, the Company also presented its plans to regain compliance with the Equity Rule to the Panel. In addition, on September 15, 2023, the Company received a written notice form Nasdaq that it no longer meets the minimum 500,000 publicly held shares requirement for The Nasdaq Capital Market and it no longer complies with Nasdaq Listing Rule 5550(a)(4) (the “Public Float Rule”). The September notification letter stated that the Panel will consider this matter in their decision regarding the Company’s continued listing on The Nasdaq Capital Market.
On September 29, 2023, the Company received a written notice from Nasdaq that the Panel had granted the Company an exception through December 26, 2023, to allow the Company to complete its compliance with the Equity Rule. The October notification letter also confirmed that the Company had demonstrated compliance with the Minimum Bid Price Rule and granted the Company an exception through December 26, 2023 to allow the Company to demonstrate compliance with the Public Float Rule.
If we are delisted from Nasdaq, but obtain a substitute listing for our common stock, it will likely be on a market with less liquidity, and therefore experience potentially more price volatility than experienced on Nasdaq. Stockholders may not be able to sell their shares of common stock on any such substitute market in the quantities, at the times, or at the prices that could potentially be available on a more liquid trading market. As a result of these factors, if our common stock is delisted from Nasdaq, the value and liquidity of our common stock, warrants and pre-funded warrants would likely be significantly adversely affected. A delisting of our common stock from Nasdaq could also adversely affect our ~~business and financial condition.~~
~~Our business could be adversely affected by general conditions in the global economy and in the global financial markets, including conditions that are outside of~~ability to obtain financing for our control, including the impact of health and safety concerns, such as those relating to the current COVID-19 novel coronavirus (“COVID-19”) pandemic. The recent global financial crisis in connection with the COVID-19 pandemic has caused extreme volatility and disruptions in the capital and credit markets. A severe operations and/or ~~prolonged economic downturn could~~ result in a ~~variety~~loss of ~~risks to our~~confidence by investors, employees and/or business including our ability to raise additional capital when needed on acceptable terms, if at all. Any of the foregoing could harm our business and we cannot anticipate all the ways in which the current economic climate and financial market conditions could adversely impact our business.partners.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
(a) ~~(a)~~ Sales of Unregistered Securities
~~During the three months ended June 30, 2020, 30,975 warrants were exercised for 30,975 shares of common stock. The company recognized proceeds of $185,850 related to the exercise.~~
~~During the three months ended June 30, 2020,~~On March 17, 2023, the Company issued ~~17,500~~a consultant 4,675 shares of common stock ~~to two consultants~~ for ~~services.~~services rendered.
~~(b)~~ ~~Use of IPO Proceeds~~
On July 2, 2020, the Company completed its initial public offering (“IPO”). In connection therewith, the Company issued 1,226,668 Units (the “Units”), excluding the underwriters’ option to cover overallotments, at an offering price of $9.00 per Unit, resulting in gross proceeds of approximately $11.0 million. The Units issued in the IPO consisted of one share of common stock, one Series A warrant, and one Series B warrant. The Series A warrants have an exercise price of $9.00 and a term of 5 years. The Series B warrants have exercise price of $11.25 and a term of 5 years. Substantially all of the Series B warrants issued in the IPO have been exercisedissuance above was made pursuant to ~~a cashless provision therein.~~
~~We received net proceeds~~an exemption from registration under the Securities Act of $5.8 million, after deducting underwriting discounts and commissions and offering expenses borne by us. No payments were made by us to directors, officers or persons owning ten percent or more of our common stock or to their associates, or to our affiliates, other than payments in the ordinary course of business to officers for salaries and to non-employee directors1933, as amended, pursuant to ~~our director compensation policy.~~ ~~Dawson James Securities, Inc. acted as lead book-running manager of the offering and as representative of the underwriters~~ ~~for the offering.~~
~~There has been no material change in the planned use of proceeds from our IPO from that described in the final prospectus related to the offering, dated June 29, 2020 as filed with the SEC.~~
Section 4(a)(2) thereof.
~~-22-~~
38

Item 3. Defaults Upon Senior Securities
None.
Item 4. Mine Safety Disclosures
Not applicable.
Item 5. Other Information
None.
Item 6. Exhibits
Exhibit Incorporated by Reference Filed
Number Exhibit Description Form File No. Exhibit Filing Date Herewith

3.1 Amended and Restated Certificate of Incorporation of the Registrant. S-1 333-235933 3.1 June 25, 2020

3.2
Certificate of Amendment, dated June 29, 2020 X

3.3 Amended and Restated Bylaws of the Registrant S-1 333-235933 3.3 June 25, 2020

10.1
Amendment Agreement, dated July 1, 2020, by and between the Company and Loma Linda University X

31.1* Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. X

31.2* Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. X

32.1* Certification of Principal Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. X

32.2* Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. X

101.INS XBRL Instance Document X

101.SCH XBRL Taxonomy Extension Schema Document X

101.CAL XBRL Taxonomy Extension Calculation Linkbase Document X

101.DEF XBRL Taxonomy Extension Definition Linkbase Document X

101.LAB XBRL Taxonomy Extension Label Linkbase Document X

101.PRE XBRL Taxonomy Extension Presentation Linkbase Document X
+Exhibit ~~Indicates a management contract or compensatory plan or arrangement.~~
*Number ~~This certification is deemed not filed for purposes~~ Exhibit Description
31.1* Certification of ~~Section 18 of~~Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as ~~amended (Exchange Act), or otherwise subject~~adopted pursuant to Section 302 of the ~~liability~~Sarbanes-Oxley Act of ~~that section, nor shall it be deemed incorporated by reference into any filing~~2002.
31.2* Certification of Principal Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of ~~1933,~~1934, as ~~amended, or~~adopted pursuant to Section 302 of the ~~Exchange Act.~~Sarbanes-Oxley Act of 2002.
32.1** Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS* Inline XBRL Instance Document.
101.SCH* Inline XBRL Taxonomy Extension Schema Document.
101.CAL* Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF* Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB* Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE* Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104* Cover Page Interactive Data File (the cover page from the Registrant’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 is formatted as Inline XBRL and contained in the Exhibit 101 XBRL Document Set).
* Filed herewith.
** Furnished herewith.
~~-23-~~
39

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
~~Aditx Therapeutics,~~Aditxt, Inc.
Date: ~~August 13, 2020~~November 14, 2023 By: /s/ Amro Albanna
Amro Albanna
Chief Executive Officer

(Principal Executive Officer)
Date: November 14, 2023 By: /s/ Thomas J. Farley
~~Date: August 13, 2020~~ ~~By:~~ ~~/s/ Corinne Pankovcin~~Thomas J. Farley
~~Corinne Pankovcin~~
Chief Financial Officer
(Principal Financial and Accounting Officer)
~~-24-~~
40
135.88 210.93 720.55 47.95 157584 203247 27017 35829 185621 P0Y 308479 false --12-31 Q3 0001726711 iso4217:USD xbrli:shares

	June 30,			December 31,
	2020			2019

ASSETS

CURRENT ASSETS:
Cash	$	49,925		$	4,090
Prepaid expenses		25,083			-

TOTAL CURRENT ASSETS		75,008			4,090

Deferred offering costs		542,581			119,442

TOTAL ASSETS	$	617,589		$	123,532

LIABILITIES AND STOCKHOLDERS' DEFICIT

CURRENT LIABILITIES:
Accounts payable and accrued expenses	$	2,268,581		$	1,847,458
Accrued compensation to related parties		1,220,629			962,651
Notes payable - related party		10,000			10,000
Notes payable, net of discount		830,600			155,600

TOTAL CURRENT LIABILITIES		4,329,810			2,975,709

TOTAL LIABILITIES		4,329,810			2,975,709

COMMITMENTS AND CONTINGENCIES

STOCKHOLDERS’ DEFICIT
Preferred stock, $0.001 par value, 3,000,000 shares authorized, zero shares issued and outstanding, respectively		-			-
Common stock, $0.001 par value, 27,000,000 shares authorized, 4,069,115 and 3,915,900 shares issued and 3,968,312 and 3,821,087 shares outstanding, respectively		4,069			3,916
Treasury stock, 100,803 and 94,813 shares, respectively		(201,605	)		(189,625	)
Additional paid-in capital		9,938,946			9,063,483
Accumulated deficit		(13,453,631	)		(11,729,951	)
TOTAL STOCKHOLDERS' DEFICIT		(3,712,221	)		(2,852,177	)

TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$	617,589		$	123,532

	September 30,			December 31,
	2023			2022
ASSETS
CURRENT ASSETS:
Cash	$	1,651,354		$	2,768,640
Accounts receivable, net		362,708			527,961
Inventory		858,106			950,093
Prepaid expenses		555,631			496,869
TOTAL CURRENT ASSETS		3,427,799			4,743,563

Fixed assets, net		2,003,859			2,318,863
Intangible assets, net		26,750			107,000
Deposits		312,265			355,366
Right of use asset - long term		2,454,886			3,160,457
Deferred issuance costs		-			50,000
TOTAL ASSETS	$	8,225,559		$	10,735,249

LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)
CURRENT LIABILITIES:
Accounts payable and accrued expenses	$	4,224,425		$	1,958,502
Notes payable, net of discount		4,020,055			-
Financing on fixed assets		147,823			409,983
Deferred rent		169,633			188,581
Lease liability - current		1,081,377			1,086,658
Settlement liability		1,600,000			-
TOTAL CURRENT LIABILITIES		11,243,313			3,643,724

Lease liability - long term		1,203,876			1,885,218

TOTAL LIABILITIES		12,447,189			5,528,942

STOCKHOLDERS’ EQUITY (DEFICIT)
Preferred stock, $0.001 par value, 3,000,000 shares authorized, zero shares issued and outstanding, respectively		-			-
Series B Preferred stock, $0.001 par value, 1 share authorized, zero and zero shares issued and outstanding, respectively		-			-
Series C Preferred stock, $0.001 par value, 1 share authorized, zero and zero shares issued and outstanding, respectively		-			-
Common stock, $0.001 par value, 100,000,000 shares authorized, 367,902 and 107,698 shares issued and 367,851 and 107,647 shares outstanding, respectively		368			108
Treasury stock, 51 and 51 shares, respectively		(201,605	)		(201,605	)
Additional paid-in capital		112,599,764			100,448,166
Accumulated deficit		(116,620,157	)		(95,040,362	)
TOTAL STOCKHOLDERS’ EQUITY (DEFICIT)		(4,221,630	)		5,206,307

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)	$	8,225,559		$	10,735,249

	Three Months Ended			Three Months Ended			Six Months Ended			Six Months Ended
	June 30, 2020			June 30, 2019			June 30, 2020			June 30, 2019

OPERATING EXPENSES
General and administrative expenses, includes $160,329, $2,098,759, $689,766 and $2,822,367 in stock-based compensation		367,338			2,511,438		$	1,223,765		$	3,711,221
Research and development, includes $0, $0, $0 and $0 in stock-based compensation		28,294			43,978			228,665			88,846
Sales and marketing, includes $0, $0, $0 and $0 in stock-based compensation		2,848			109			2,848			147
Total Operating Expenses		398,480			2,555,525			1,455,278			3,800,214

NET LOSS FROM OPERATIONS		(398,480	)		(2,555,525	)		(1,455,278	)		(3,800,214	)

OTHER INCOME (EXPENSE)
Interest expense		(448	)		(448	)		(902	)		(1,027	)
Gain on forgiveness of debt		-			-			32,500			45,000
Amortization of debt discount		(135,389	)		-			(300,000	)		-
Total Other Income (Expense)		(135,837	)		(448	)		(268,402	)		43,973
Net loss before income taxes		(534,317	)		(2,555,973	)		(1,723,680	)		(3,756,241	)
Income tax provision		-			-			-			-

NET LOSS	$	(534,317	)	$	(2,555,973	)	$	(1,723,680	)	$	(3,756,241	)

Net loss per share - basic and diluted	$	(0.14	)	$	(0.67	)	$	(0.44	)	$	(0.98	)

Weighted average number of shares outstanding during the period - basic and diluted		3,929,205			3,842,967			3,917,891			3,821,278

	Three Months Ended			Three Months Ended			Nine Months Ended			Nine Months Ended
	September 30, 2023			September 30, 2022			September 30, 2023			September 30, 2022
REVENUE
Sales	$	124,486		$	323,125		$	563,879		$	748,119
Cost of goods sold		106,922			233,684			470,969			596,613
Gross Profit		17,564			89,441			92,910			151,506

OPERATING EXPENSES
General and administrative expenses $103,031, $461,492, $484,502, and $1,288,829 in stock-based compensation, respectively		7,169,863			3,919,618			15,209,789			12,332,728
Research and development, includes $49,209, $170,066, $165,382, and $473,593 in stock-based compensation, respectively		898,724			1,570,540			2,771,100			4,186,842
Sales and marketing $1,752, $0, $6,787, and $754,699 in stock-based compensation, respectively		44,186			(8,553	)		223,562			911,988
Total operating expenses		8,112,773			5,481,605			18,204,451			17,431,558

NET LOSS FROM OPERATIONS		(8,095,209	)		(5,392,164	)		(18,111,541	)		(17,280,052	)

OTHER EXPENSE
Interest expense		(906,104	)		(645,381	)		(2,389,627	)		(742,701	)
Interest income		367			10,084			9,784			30,131
Other income		-			-			-			58,960
Amortization of debt discount		(744,956	)		(1,530,102	)		(921,242	)		(1,533,048	)
Total other expense		(1,650,693	)		(2,165,399	)		(3,301,085	)		(2,186,658	)

Net loss before income taxes		(9,745,902	)		(7,557,563	)		(21,412,626	)		(19,466,710	)
Income tax provision		-			-			-			-

NET LOSS	$	(9,745,902	)	$	(7,557,563	)	$	(21,412,626	)	$	(19,466,710	)

Implied Dividends		(167,169	)		-			(167,169	)		-

NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS	$	(9,913,071	)	$	(7,557,563	)	$	(21,579,795	)	$	(19,466,710	)

Net loss per share - basic and diluted	$	(48.77	)	$	(210.93	)	$	(136.94	)	$	(720.54	)

Weighted average number of shares outstanding during the period - basic and diluted		203,247			35,829			157,584			27,017

										Additional					Total
	Common						Treasury			Paid-in		Accumulated			Stockholders'
	Shares			Par			Shares			Capital		Deficit			Deficit

Balance December 31, 2019		3,821,087		$	3,916		$	(189,625	)	$	9,063,483	$	(11,729,951	)	$	(2,852,177	)

Issuance of shares for services		104,750			105			-			418,895		-			419,000

Stock option and warrant compensation		-			-			-			110,437		-			110,437

Treasury stock		(5,990	)		-			(11,980	)		-		-			(11,980	)

Net loss		-			-			-			-		(1,189,363	)		(1,189,363	)

Balance March 31, 2020 (unaudited)		3,919,847		$	4,021		$	(201,605	)	$	9,592,815	$	(12,919,314	)	$	(3,524,083	)

Exercise of warrants		30,975			31			-			185,819		-			185,850

Stock option and warrant compensation		-			-			-			77,138		-			77,138

Issuance of shares for services		17,500			18			-			83,174		-			83,192

Adjustment to Common Shares due to reverse stock split		(10	)		(1	)		-			-		-			(1	)

Net loss		-			-			-			-		(534,317	)		(534,317	)

Balance June 30, 2020 (unaudited)		3,968,312		$	4,069		$	(201,605	)	$	9,938,946	$	(13,453,631	)	$	(3,712,221	)

	Preferred Shares Outstanding		Preferred Shares Par		Preferred B Shares Outstanding		Preferred B Shares Par		Preferred C Shares Outstanding			Preferred C Shares Par		Common Shares Outstanding		Common Shares Par		Treasury Stock			Additional Paid-in Capital			Accumulated Deficit			Total Stockholders’ Equity (Deficit)
Balance December 31, 2022		-	$	-		-	$	-		-		$	-		107,647	$	108	$	(201,605	)	$	100,448,166		$	(95,040,362	)	$	5,206,307

Stock option and warrant compensation		-		-		-		-		-			-		-		-		-			59,964			-			59,964

Restricted stock unit compensation		-		-		-		-		-			-		-		-		-			111,187			-			111,187

Issuance of shares for vested restricted stock units		-		-		-		-		-			-		44		1		-			(1	)		-			-

Sale of common stock															8,463		9		-			507,007			-			507,016

Issuance of shares for services		-		-		-		-		-			-		4,675		5		-			168,295			-			168,300

Net loss		-		-		-		-		-			-		-		-		-			-			(5,984,706	)		(5,984,706	)

Balance March 31, 2023		-	$	-		-	$	-		-		$	-		120,829	$	123	$	(201,605	)	$	101,294,618		$	(101,025,068	)	$	68,068

Stock option and warrant compensation		-		-		-		-		-			-		-		-		-			59,964			-			59,964

Restricted stock unit compensation		-		-		-		-		-			-		-		-		-			103,264			-			103,264

Issuance of shares for vested restricted stock units		-		-		-		-		-			-		42		1		-			(1	)		-			-

Warrants issued for cash, net of issuance costs		-		-		-		-		-			-		-		-		-			1,581,467			-			1,581,467

Exercise of warrants		-		-		-		-		-			-		48,184		49		-			(49	)		-			-

Net loss		-		-		-		-		-			-		-		-		-			-			(5,682,018	)		(5,682,018	)

Balance June 30, 2023		-	$	-		-	$	-		-		$	-		169,055	$	173	$	(201,605	)	$	103,039,263		$	(106,707,086	)	$	(3,869,255	)

Stock option compensation		-		-		-		-		-			-		-		-		-			59,964			-			59,964

Restricted stock unit compensation		-		-		-		-		-			-		-		-		-			94,028			-			94,028

Issuance of restricted stock units for compensation		-		-		-		-		-			-		71		-		-			-			-			-

Sale of Series C Preferred shares to related party		-		-		-		-		1			-		-		-		-			1,000			-			1,000

Issuance of shares for debt issuance costs		-		-		-		-		-			-		21,184		22		-			271,984			-			272,006

Issuance of warrants for offering, net of issuance costs		-		-		-		-		-			-		-		-		-			8,966,400			-			8,966,400

Exercise of warrants		-		-		-		-		-			-		136,190		137		-			(8	)		-			129

Rounding from reverse stock split		-		-		-		-		-			-		41,351		36		-			(36	)		-			-

Modification of warrants		-		-		-		-		-			-		-		-		-			167,169			(167,169	)		-

Redemption of Series C Preferred shares to related party		-		-		-		-		(1	)		-		-		-		-			-			-			-
Net loss		-		-		-		-		-			-		-		-		-			-			(9,745,902	)		(9,745,902	)

Balance September 30, 2023		-	$	-		-	$	-		-		$	-		367,851	$	368	$	(201,605	)	$	112,599,764		$	(116,620,157	)	$	(4,221,630	)

	Six Months Ended			Six Months Ended
	June 30, 2020			June 30, 2019
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(1,723,680	)	$	(3,756,241	)
Adjustments to reconcile net loss to net cash used in operating activities
Stock-based compensation		689,766			2,822,367
Amortization of debt discount		300,000			-
Changes in operating assets and liabilities:
Prepaid expenses		(25,083	)		-
Accounts payable and accrued expenses		95,429			365,653
Accrued compensation to related parties		257,978			259,014
Net cash used in operating activities		(405,590	)		(309,207	)

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from notes payable - related party		-			10,000
Proceeds from notes payable		375,000			-
Repayments of notes payable - related party		-			(42,502	)
Repayments of notes payable		-			(5,000	)
Common stock issued for cash, net of issuance costs		-			235,464
Deferred offering costs		(109,425	)		-
Exercise of warrants		185,850			-
Net cash provided by financing activities		451,425			197,962

NET INCREASE (DECREASE) IN CASH		45,835			(111,245	)

CASH AT BEGINNING OF PERIOD		4,090			115,709

CASH AT END OF PERIOD	$	49,925		$	4,464

Supplemental cash flow information:
Cash paid for income taxes	$	-		$	-
Cash paid for interest expense	$	-		$	-

NON-CASH INVESTING AND FINANCING ACTIVITIES:
Liabilities assumed for common stock	$	11,980		$	90,712
Deferred offering costs accrued and payable	$	313,714		$	-
Original issuance discount on notes payable	$	300,000		$	-

Computers	Three years to five years
Lab Equipment	Seven to ten years
Office Furniture	Five to ten years
Other fixed assets	Five to ten years
Leasehold Improvements	Shorter of estimated useful life or remaining lease term

	Cost Basis		Accumulated Depreciation			Net
Computers	$	378,480	$	(292,655	)	$	85,825
Lab Equipment		2,585,077		(789,781	)		1,795,296
Office Furniture		56,656		(12,449	)		44,207
Other Fixed Assets		8,605		(1,869	)		6,736
Leasehold Improvements		120,440		(48,645	)		71,795
Total Fixed Assets	$	3,149,258	$	(1,145,399	)	$	2,003,859

	Cost Basis		Accumulated Amortization			Net
Proprietary Technology	$	321,000	$	(294,250	)	$	26,750
Total Intangible Assets	$	321,000	$	(294,250	)	$	26,750

~~Exercise price~~	~~$ 4.00-11.00~~
~~Expected dividend yield~~		0	%
~~Risk free interest rate~~		~~0.39% - 2.65~~	%
~~Expected life in years~~		~~2.79-7.52~~
~~Expected volatility~~		~~141-146~~	%

			Weighted Average		Weighted Average
	Number		Exercise Price		Remaining Life
Stock Options
Outstanding December 31, 2019		1,102,500	$	4.00		7.77
Granted		7,500		11.00		7.52
Expired or forfeited		-		-		-
Outstanding June 30, 2020 (unaudited)		1,110,000	$	4.05		7.25

Nonvested Options	Shares			Weighted- Average Exercise Price
Nonvested at December 31, 2019		-		$	-
Granted		7,500			11.00
Vested		(7,500	)		11.00
Forfeited		-			-
Nonvested at June 30, 2020 (unaudited)		-		$	-

	Number			Weighted Average Exercise Price		Weighted Average Remaining Life
Warrants
Outstanding December 31, 2019		1,382,478			4.44		2.84
Granted		5,000			11.00		3.00
Forfeited		(65,000	)		4.00		-
Exercised		(30,975	)		6.00		-
Outstanding June 30, 2020 (unaudited)		1,291,503		$	4.46		2.32

Nonvested Warrants	Shares			Weighted- Average Exercise Price
Nonvested at December 31, 2019		200,000			4.00
Granted		5,000			-
Vested		-			-
Forfeited		(65,000	)		-
Nonvested at June 30, 2020 (unaudited)		140,000		$	4.00

	Nine Months Ended September 30, 2023		Nine Months Ended September 30, 2022
Components of total lease costs:
Operating lease expense	$	963,213	$	988,381
Total lease costs	$	963,213	$	988,381

	September 30, 2023		December 31, 2022
Assets
Right of use asset – long term	$	2,454,886	$	3,160,457
Total right of use asset	$	2,454,886	$	3,160,457

Liabilities
Operating lease liabilities – short term	$	1,081,377	$	1,086,658
Operating lease liabilities – long term		1,203,876		1,885,218
Total lease liability	$	2,285,253	$	2,971,876

Weighted average remaining lease term (in years) – operating leases			2.29
Weighted average discount rate – operating leases			8.00	%

2023 (remaining)	$	285,991
2024		1,004,982
2025		710,546
2026		423,930
Total lease payments	$	2,425,449
Less imputed interest		(140,194	)
Less current portion		(1,081,377	)
Total maturities, due beyond one year	$	1,203,876

	(i)	Satisfactory completion of due diligence;

	(ii)	Completion by the Company of financing sufficient to consummate the transactions contemplated by the Asset Purchase Agreement;

	(iii)	Receipt by the Company of all required Consents from Governmental Bodies for the Acquisition, including but not limited to, any consents required to complete the transfer and assignment of Cellvera’s membership interests in GRA;

	(iv)	Receipt of executed payoff letters reflecting the amount required to be fully pay all of each of Seller’s and Seller Owner’s Debt to be paid at Closing;

	(v)	Receipt by the Company of a release from Agility;

	(iv)	Execution of an agreement acceptable to the Company with respect to the acquisition by the Company of certain intellectual property presently held by a third party;

	(v)	Execution of an amendment to an asset purchase agreement previously entered into by Cellvera with a third party that effectively grants the Company the rights to acquire the intellectual property from the third party under such agreement;

	(vi)	Receipt of a fairness opinion by the Company with respect to the transactions contemplated by the Asset Purchase Agreement; and

	(vii)	Receipt by the Company from the Seller Owner of written consent, whether through its official liquidator or the Board of Directors of Seller Owner, to the sale and purchase of the Acquired Assets and Assumed Liabilities pursuant to the Assert Purchase Agreement.

Vested and Nonvested Stock Options	Number		Weighted Average Exercise Price		Weighted Average Remaining Life
Outstanding December 31, 2022		1,127	$	6,802.93		5.74
Granted		-		-		-
Exercised		-		-		-
Expired or forfeited		-		-		-
Outstanding September 30, 2023		1,127	$	6,802.93		5.00

Nonvested Stock Options	Number			Weighted- Average Exercise Price
Nonvested on December 31, 2022		55		$	3,840
Granted		-			-
Vested		(55	)		3,840
Forfeited		-			-
Nonvested on September 30, 2023		-		$	-

Exercise price	$	10.00-12.50
Expected dividend yield		0	%
Risk free interest rate		4.44	%
Expected life in years		5.50
Expected volatility		171	%

Vested and Nonvested Warrants	Number			Weighted Average Exercise Price		Weighted Average Remaining Life
Outstanding December 31, 2022		127,281		$	514.97		4.54
Granted		2,190,367			6.36		5.20
Exercised		(184,374	)		1.35		-
Expired or forfeited		(392	)		8,250.00		-
Outstanding September 30, 2023		2,132,882		$	35.22		5.10

Nonvested RSUs	Number			Weighted Average Price
Nonvested December 31, 2022		187		$	1,856,21
Granted		-			-
Vested		(170	)		2,714.15
Forfeited		(35	)		1,345.77
Rounding for Reverse Split		18			-
Nonvested September 30, 2023		-		$	-

	Payment Due by Year
	Total		2023		2024		2025		2026
Lease	$	2,425,449	$	285,991	$	1,004,982	$	710,546	$	423,930

*Number	~~This certification is deemed not filed for purposes~~	Exhibit Description
31.1*		Certification of ~~Section 18 of~~Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as ~~amended (Exchange Act), or otherwise subject~~adopted pursuant to Section 302 of the ~~liability~~Sarbanes-Oxley Act of ~~that section, nor shall it be deemed incorporated by reference into any filing~~2002.
31.2*		Certification of Principal Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of ~~1933,~~1934, as ~~amended, or~~adopted pursuant to Section 302 of the ~~Exchange Act.~~Sarbanes-Oxley Act of 2002.
32.1**		Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS*		Inline XBRL Instance Document.
101.SCH*		Inline XBRL Taxonomy Extension Schema Document.
101.CAL*		Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF*		Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB*		Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE*		Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104*		Cover Page Interactive Data File (the cover page from the Registrant’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 is formatted as Inline XBRL and contained in the Exhibit 101 XBRL Document Set).

	~~Aditx Therapeutics,~~Aditxt, Inc.

Date: ~~August 13, 2020~~November 14, 2023	By:	/s/ Amro Albanna
		Amro Albanna
		Chief Executive Officer (Principal Executive Officer)

Date: November 14, 2023	By:	/s/ Thomas J. Farley
~~Date: August 13, 2020~~	~~By:~~	~~/s/ Corinne Pankovcin~~Thomas J. Farley
		~~Corinne Pankovcin~~
		Chief Financial Officer (Principal Financial and Accounting Officer)